Podcasts about Chief scientific officer

A hundred million degrees Celsius. That's the brutal reality of commercial fusion. This week, we're sitting down with industry leaders to discuss the front lines of an energy revolution, from surviving extreme thermal stress to building brand-new supply chains.We Meet:  Joe Paluska is the CMO of Commonwealth Fusion SystemsAnnie Kritcher is the Co-Founder and Chief Scientist at InertiaAlice Brooks is a Board Member & Partner at Khosla VenturesCary Forest is the Co-Founder & Chief Scientific Officer at Realta FusionCredits:This episode of SHIFT was produced by Jennifer Strong with help from Emma Cillekens. It was mixed by Garret Lang, with original music from him and Jacob Gorski. Art by Meg Marco.

Day Break | The Truth About America Is Going Global --- 00:00 - Monologue 19:15 – Terris E. Todd, Director of Coalitions & Outreach for the Project 21 Black Leadership Network. Todd discusses the importance of fatherhood, particularly within Black communities, and explores how strong families, mentorship, faith, and community leadership can positively impact future generations. 28:12 – Dr. Peter A. McCullough, MD, MPH, Chief Scientific Officer at The Wellness Company. McCullough discusses recently released documents concerning U.S.-funded biological research laboratories around the world and the ongoing debate surrounding government transparency and oversight. He also addresses concerns about tick-borne illnesses during summer months, Lyme disease prevention, and preparedness strategies for individuals seeking access to critical medications. 38:23 - Monologue Featuring Ivey Gruber 47:20 – Gregory Wrightstone, geologist, Executive Director of the CO2 Coalition, and bestselling author of A Very Convenient Warming. Wrightstone discusses utility regulation, energy markets, and concerns that monopoly utility structures may contribute to higher costs for consumers while limiting competition and choice. 57:36 – Diana Furchtgott-Roth, economist, policy expert, and Distinguished Fellow at the Energy Policy Research Foundation (EPRINC). Furchtgott-Roth examines declining oil prices and explains what lower energy costs could mean for inflation, consumer spending, economic growth, and the broader U.S. economy. 1:06:33 – Carrie Sheffield, Director of the Center for AI and Technology at Independent Women. Sheffield discusses a House Energy and Commerce Committee hearing focused on healthcare price transparency and efforts to provide consumers with clearer information about healthcare costs and pricing. 1:16:49 - Monologue 1:25:45 – Ron Rademacher, travel writer, author, storyteller, and Michigan travel expert. Rademacher highlights festivals, community events, outdoor activities, and travel destinations taking place across Michigan during the week and upcoming weekend. 1:33:55 – Tim Golding, Michigan State Director for Americans for Prosperity. Golding discusses AFP-Michigan's concerns regarding proposed public subsidies connected to Detroit's Renaissance Center redevelopment and examines broader questions about taxpayer-funded economic development incentives. 1:44:49 – Ivey Gruber, President of the Michigan Talk Network. Gruber discusses the role of personal beliefs and expression in professional sports, examining debates over religious messages, league policies, and whether sports organizations should regulate or promote certain forms of social, political, or religious expression by athletes. --- Check out our brand new podcast, 'Forgotten America'... Episode 19 is live NOW at Steve Gruber on YouTube! Link below: https://youtu.be/rulxGa_tTeE

In this episode of Data in Biotech, host Ross Katz sits down with Paul Finn, Chief Scientific Officer at Oxford Drug Design, for a conversation on what it actually takes to find a drug molecule that works not just on paper but also in the lab, in the cell, and, ultimately, in the clinic. Paul brings four decades of experience across what became GSK, Pfizer, and a series of Oxford-area spinouts and has shepherded a compound all the way to a marketed drug. That perspective gives him a particular kind of skepticism toward AI results that look too good to be true because he's done the work of checking whether they are. The conversation moves through synthesizability as a first-class constraint, why chemistry has proven so much harder for AI than biology, how 3D molecular representation gets closer to the physics that actually matters, and what rigorous multi-parameter optimization looks like when you're trying to kill cancer cells and drug-resistant bacteria at the same time. What you'll learn in this episode: >> Why synthesizability is chronically underestimated and why changing a single atom in a structure can take a molecule from trivially easy to make to practically impossible >> How Oxford Drug Design constrains the generative search to reaction schemes and purchasable building blocks, and why that chemical space is still so vast that novelty is not meaningfully sacrificed >> Why most generative AI models learn from a 2D string representation of a molecule; two steps removed from the 3D physics that govern how a drug actually binds to its target >> How Bayesian optimization over reagent space, rather than molecular space, allows an active learning loop to focus on the structural patterns associated with activity >> Why benchmarking complex models against simple ones is the discipline that exposes false correlations and why Paul and his co-authors were able to recover the Halicin result using methods decades older than deep learning >> What a pharma company should actually ask an AI drug discovery vendor before buying what they're selling Meet our guest: Paul Finn is Chief Scientific Officer at Oxford Drug Design, a computational drug discovery company with roots in Oxford's chemistry department. His career spans over 40 years of computational drug discovery, from early structure-activity modeling in the 1980s through to modern generative AI methods, with deep experience at what became GSK and Pfizer before moving into the Oxford spinout ecosystem. At Oxford Drug Design, Paul leads internal programs in oncology and antibacterial resistance, combining novel computational methods with a rigorous, synthesizability-first approach to multi-parameter optimization. Connect with Paul Finn on LinkedIn: https://uk.linkedin.com/in/paul-finn-2250616 About the host: Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Ross Katz on LinkedIn: https://www.linkedin.com/in/b-ross-katz/ Connect with us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode! Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. https://www.linkedin.com/company/corrdyn/

I sit down with nutrition scientist Dr. Luke Bucci to explore the powerful connection between blood flow, nitric oxide, mitochondrial health, and healthy aging. We discuss why circulation impacts nearly every function in the body, what causes energy levels to decline with age, and how nutrition, exercise, and targeted supplementation may help support long-term vitality. Dr. Bucci also explains the science behind nitric oxide, blood sugar regulation, and the role mitochondria play in keeping us energized and resilient throughout life.Dr. Luke Bucci, PhD, CNS, CCN is the Chief Scientific Officer of Juvenon and a biomedical scientist with more than 40 years of experience in nutrition, dietary supplements, and clinical laboratory science. He earned his PhD in Biomedical Sciences from the University of Texas Health Science Center at Houston and has helped develop numerous patented nutritional products used worldwide. A recognized authority in healthy aging, sports nutrition, omega-3s, probiotics, and dietary supplement science, Dr. Bucci has authored scientific books, taught university-level courses, and received multiple industry awards for his contributions to nutrition and health innovation.Links mentioned during this episode:Juvenon: https://juvenon.com/Free Initial Consultation with Dr. Megan: https://p.bttr.to/3a9lfYkLyons' Share Instagram: www.instagram.com/thelyonsshareJoin Megan's newsletter: www.thelyonsshare.org/newsletter

Are you a dermatologist curious about clinical research — or a seasoned trialist looking to reignite your passion? In this episode of the Science of Skin Podcast, Dr. Ted Lane (Austin, TX) sits down with Dr. Jason Hawkes, Chief Scientific Officer at Oregon Medical Research Center, to pull back the curtain on what it really means to build a career in dermatology clinical trials. From navigating the growing complexity of modern trial protocols to reframing the pharma-physician relationship, Ted and Jason share candid insights that only experienced clinical trialists can offer. They discuss how running trials makes you a sharper diagnostician, why medical dermatology remains one of the most rewarding specialties, and how industry partnerships open unexpected academic and commercial doors. You'll also hear their honest takes on mentorship — including the must-read JAMA article Mentorship Malpractice — and why thinking of your career as a lattice, not a ladder may be the most liberating shift you can make. Whether you're five years into practice or just starting out, this episode is packed with hard-won wisdom on building a meaningful, intellectually stimulating career in dermatology.

We are excited to host Grace Blest-Hopley on this episode of the Mangu.tv podcast. Dr Grace Blest-Hopley is a neuroscientist with over a decade of research into cannabinoids and psychedelics, and the founder of Hystelica — the world's first research organisation dedicated to understanding female biology for safer, more effective psychedelic use, delivering both original research and education in the field. She holds a PhD in Neuroscience from King's College London, and now serves as Chief Scientific Officer at NWPharmaTech and Research Director at Heroic Hearts Project, where she leads work supporting military veterans living with trauma. Grace has spoken internationally as part of her advocacy for women's representation in psychedelic science.   Grace discusses her upbringing on a Staffordshire farm, her connection to horses, and how experiences in India led her to study neuroscience. She and Giancarlo explore the therapeutic potential of cannabinoids, the challenges of cannabis research, and findings from neuroimaging studies of long-term users, particularly those who started young.Their conversation also covers the rise of psychedelic-assisted therapy, the importance of preparation and integration, and Grace's work with the Heroic Hearts Project, where she witnessed the benefits of Ayahuasca ceremonies with the Shipibo people. Grace explains how psychedelics may create a window of increased neuroplasticity, offering opportunities to rewire the brain. She also discusses her research into women's health, examining how hormonal fluctuations throughout the menstrual cycle can influence psychedelic experiences and their therapeutic potential.

Protect Your Retirement with a PHYSICAL Gold and/or Silver IRA https://www.sgtreportgold.com/ CALL( 877) 646-5347 - You Can Trust Noble Gold   Dr. Peter McCullough the Chief Scientific Officer of The Wellness Company returns to SGT Report to drop bombshells about the untimely death of NASCAR superstar Kyle Busch, the Lone Star tick agenda, how to get $1600 per year in FREE supplements of your choice (2 per month), and much, much more. Thanks for tuning in.   **Get unlimited TELE-HEALTHCARE from HONEST Doctors and TWO FREE Vitamin Supplements of your choice EVERY MONTH at The Wellness Company with the 'WELLNESS ELITE' membership. USE CODE SGT TO SAVE 10%!! https://www.TWC.health/SGT Remove heavy metals, graphene oxide & nanotech from your blood w/ MaterPeace: https://masterpeacebyhcs.com/?ref=4094 https://old.bitchute.com/video/sXeTMZstHijT/

In this episode of Manufacturing Unscripted, host Peter Parsons sits down with Juha Pitkänen, co-founder and Chief Scientific Officer of Solar Foods, to talk about a protein literally made out of thin air. Juha explains how Solar Foods uses CO2, hydrogen, and renewable electricity to grow a microorganism that becomes Solein, a yellow protein powder already approved in Singapore and the US. A fascinating look at food production without agriculture, the regulatory road ahead, and where this technology could go next. Sponsored by Promess Inc., the leading provider of fully electric servo presses for manufacturing.   Watch on Youtube: https://youtu.be/1SnyF_Bev_Y  @ Juha-Pekka Pitkänen @Solar Foods @peter parsons    @promess   

Social determinants of health, including housing, food access, insurance status, and structural inequities, significantly influence stroke prevention, recovery, and long term outcomes. These factors affect biological risk, treatment adherence, and disparities in care, even when traditional clinical measures are addressed. This episode highlights practical strategies for integrating screening, leveraging multidisciplinary teams, and identifying opportunities for advocacy to improve patient outcomes. In this episode, Teshamae Monteith, MD, FAAN, speaks with Nneka L. Ifejika, MD, MPH, author of the article "Social Determinants of Health and Their Impacts on Stroke Prevention and Outcomes" in the Continuum® June 2026 Cerebrovascular Disease issue. Dr. Monteith is the associate editor of Continuum® Audio and an associate professor of clinical neurology at the University of Miami Miller School of Medicine in Miami, Florida. Dr. Ifejika is an adjunct professor of physical medicine and rehabilitation at UT Southwestern Medical Center in Dallas, Texas, and the chief scientific officer of the Division of Academics at Ochsner Health System in New Orleans, Louisiana. Additional Resources Read the article: Social Determinants of Health and Their Impacts on Stroke Prevention and Outcomes Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @headacheMD Full episode transcript available here Dr Monteith: Two patients have the same stroke, but when they return, they have very different outcomes. We can look into some of their comorbidities, but something we don't spend enough time talking about is the social determinants of health. Stay tuned to this discussion. I promise you, you'll become a better neurologist. Dr Jones: This is Dr. Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Monteith: This is Dr. Teshamae Monteith. Today I'm interviewing Dr. Nneka Ifejika about her article on social determinants of health and their impacts on stroke prevention and outcomes. This article appears in the June 2026 Continuum issue on cerebrovascular disease. How are you? Welcome to our podcast. Dr Ifejika: Thanks for having me. I'm doing great. Dr Monteith: Great. So, can you introduce yourself to our audience? Dr Ifejika: Sure. I'm Dr. Nneka Ifejika. I am the Chief Scientific Officer of Ochsner Health System in New Orleans, Louisiana. But I'm also a cerebrovascular rehabilitation doctor. I've been practicing for about nineteen years, and am happy and honored to be a contributor to this Continuum Neurology article. It's a really important topic. Dr Monteith: Great. So, what got you into this field, first of all? Dr Ifejika: Well, I was deciding between PM&R and neurology, and I was putting in both match lists. And I thought about it and I leaned toward PM&R, but stroke still had a grasp on my heart and my mind. And so, after I finished my residency, I joined the UT Houston stroke team, and I did a, thankfully did a two-year fellowship and became cross-trained in stroke as well as physical medicine rehab. So, I am a jack of both trades. Dr Monteith: So, you got your way in a way. Dr Ifejika: I did. Dr Monteith: You know, we have a lot of learners that are listening, so it's always, uh, nice for them to be inspired, I think, by people's career paths. So why don't we talk about the objectives of your article? Dr Ifejika: Sure. So, one of the most important things that we wanted to do was make sure that medical students, residents, faculty, and fellows understood the impact of social determinants of health on stroke recovery and stroke rehabilitation. It's not as simple as you have hypertension, hyperlipidemia, we're going to manage your stroke risk factors. Oh, you had an ischemic stroke. You presented in time for the window. We're going to give you endovascular therapy and then modified Rankin scale at hospital discharge in ninety days. No, no, no. The stroke survivor and their caregivers and their family have a lot more to deal with outside of what we look at during the acute stroke hospitalization and post-acute rehabilitation. Things like, can they afford the medication that we're prescribing? Antiplatelet agents or anticoagulation can be extremely expensive. Do they have housing insecurity? Is there food insecurity? What's going on behind the scenes that we are not addressing that can directly impact the admission rate and the readmission rate after we take care of a stroke survivor? Dr Monteith: I love the article because you took a real deep dive into social determinants of health, what they are, why they matter, and what we can do about them. And so why don't we talk a little bit about the NINDS framework for social determinants of health? I think many of us might not be familiar with the framework per se. Dr Ifejika: So, the framework consists of multiple domains specifically that relate to social determinants of health that were published in Neurology a couple of years ago. So, I do hope that people who are hearing this recording actually read them. There are interpersonal domains, there are classic medical domains, there are indeterminate domains, and there are six total domains. And health domains are the last domain. So, things like when it comes to housing insecurity, food insecurity, that's a domain of social determinants of health. When it comes to chronic racism, when it comes to biases that patients experience, those actually impact outcomes. So, there are six separate indices that we're going to get into in detail and how we address them as clinicians, whether it be at the medical student level, resident level, faculty level, to integrate the social determinants of health in our care plans, because we could be doing a much better job. And I think it'll be really important from the interpersonal perspective when we really relate to our patients and their families that we ask these questions. For example, if we're prescribing someone to have treatment for their diabetes mellitus and ha- and, and be taking insulin, if they have housing insecurity and they're in a homeless shelter, they have to leave the homeless shelter during the day. So, what happens to the insulin that we prescribe? These are variables that we are not considering on a regular basis, but they directly relate to compliance. Dr Monteith: Great. So that was one thing I wanted to bring up. We're very good at measuring blood pressure and trying to determine, uh, the association between stroke outcomes and things that we can measure, glucose, lipids, blood pressure. What is the evidence for social determinants of health and stroke outcome? Dr Ifejika: The evidence is growing, and there have been many publications that have come out that are, are going to be highlighted in this article related to structural determinants of health inequities, like structural racism, as well as disparities related to ethnicity and race. There's geographical disparities. For example, a lot of patients are, are primarily concerned about rural versus urban, whether you have access to different post-acute rehabilitation, whether you have access to secondary stroke prevention because you simply don't have the transportation from a, a rural area to get to a drugstore to get things available to you. Social status. There are actually publication related to socioeconomic status and the concerns when it comes to air pollution. So particulate matter 2.5, we know that that has a direct impact on stroke outcomes and health overall, but we don't really think about it as a structural determinant of health inequity. There's several multiple layers of research that have gone on specifically that have been cited in the literature that relate directly to social determinants of health and how we can address them moving forward. Dr Monteith: And what I found interesting in your article in that you gave at least a few examples where social factors like income, education were controlled for, and maybe in large part it is, but even when you control for some of these very obvious social risk factors, you still have inequities. Dr Ifejika: Absolutely. And I think it was really important to show that we had strong peer review evidence behind this, as it wasn't just something that we were creating or hypothesizing about. There have been studies that have been done over this over decades of time, showing the impacts of social determinants of health on outcomes. But the question and concern that we have is we know this growing body of literature continues to expand. What are we doing about it when it comes to education of the future generations of providers who will be caring for this population? Dr Monteith: Before we get into how, you know, what we're going to do about that, let's just kind of put that link, cause the evidence is there. How does it drive biology? Dr Ifejika: It's a great question. So, for example, particulate matter 2.5 in air pollution has been shown to have an existing impact on hypertension, raising your blood pressure. So that's a direct effect of a social determinant of health related to socioeconomic status because people who live in areas with higher air pollution are... They're not green spaces. They live near highways. Those are areas that unfortunately are also impacted by food deserts. Food deserts, if you're not able to get fresh fruits, vegetables, whole foods, increases your risk of developing diabetes, hyperlipidemia, also increases your sodium intake, again, increasing hypertension. These things are all connected to biological determinants. It's just that we're not asking about them necessarily within the social history when we're taking people into the hospital, but they have direct effects. Dr Monteith: Great. Neurologists tend to be busy and, you know, we're... have all of these things that we're being asked to do and chart and click and all of that stuff. And so how can we more readily integrate screening for social determinants of health and that conversation into the work we do? We recognize it's important. We recognize it's an important risk factor. There's a lot of these determinants. So, what is a good way to do so? And I, I know that in the paper you've, you've given different roles to different team players, so I want you to talk about that too, but just kind of even a regular routine office visit. Walk us through a way we can more easily integrate that kind of conversation. Dr Ifejika: It's an excellent question, and what I've recommended that we do in a standard office visit is utilize the time before the visit to send out screeners. So, for example, usually with an electronic medical record, you can send documents before the visit even starts, where people can check off whether they have any concerns regarding housing, food insecurity. They can check out their location of where they live, whether they live near a highway or not near a highway. It's specifically related to socioeconomic status. We can ask about insurance status, whether they have insurance, insured versus uninsured, but then also types of insurance, whether they have Medicaid insurance versus Medicare insurance. Then even drilling even further, type of Medicare insurance, Medicare Advantage versus traditional Medicare, cause all of those things actually play a role in this. Dr Ifejika: And evaluate these things and don't take time during your office visit. Send these screeners out beforehand. Have them be assimilated by your medical staff. Make sure you're utilizing every resource that you have at your disposal to help streamline things, so by the time the person comes in for the visit, you've primed the pump. You have this information already in your hands at your fingertips cause it was sent out in advance, and you have your medical staff already have an understanding of. If they didn't fill it out electronically, give it to them in the lobby. Make sure they have a handwritten copy in the lobby so that when they come into the office visit, you have the information at your fingertips. Dr Monteith: Are there any particular resources that you recommend for those types of screeners? Dr Ifejika: What I've used in the past, if you have patient-reported outcomes, so the PROMIS instruments, that's a good start. It doesn't get into the details of housing insecurity, food insecurity, but it's a good start to help prime questions and to start the conversation during your office visit. In my clinics, I do a PROMIS 27 on every patient, as well as a PHQ-9 for depression on everyone. And then I collect data longitudinally, and I can always drill down on factors that I noticed that could become a problem moving forward. Dr Monteith: Yeah. And then also in your article, you spoke a bit about this impact from the acute presentation in the hospital to rehab. Dr Ifejika: Yeah. Dr Monteith: So why don't you talk about these different entry points where we can really engage our patients and try and help reduce their burden? Dr Ifejika: Sure. So, healthcare can be quite fragmented, and the stroke patient, stroke survivor, and their family member have no grasp of that. They've had a stroke, and they may be going from the ER to the ICU to the stroke unit to the floor to the rehab unit, and we see it as multiple levels of care, multiple types of providers. They see it as one hospital. And the concern that we have is, at those branch points, things get dropped, and we have the opportunity to pick things up at those branch points. So, during the acute care hospitalization-Primarily, that's the establishment of what has happened, how we're gonna treat it, what are the variables that we can control for right now to address those determinants of health moving forward, and to specifically looking at whether they were taking medications before, whether they could afford medications before, what that looks like at hospital discharge. Is there any duplication of medications? If a person is taking Coreg and you prescribe metoprolol, but they still have the Coreg at home, should we have really prescribed the metoprolol? We're just spending money that they may have concerns when it comes to access to care and the cost of these prescriptions. So, it's the responsibility of the acute care physician to kind of look at that. Those are subtle things that we think are subtle, but they add up quickly for the family when it comes to having one group of medications that's the same class and having to buy another type. When it comes to post-acute rehabilitation, it's really an important time to screen for whether the caregiver can handle what's occurring. So specifically, if the caregiver is already burning out and the average length of stay for a stroke patient is five days and they've come to rehab for two weeks, what's gonna happen in the next two years or the next four years? So, during the post-acute rehabilitation phase, it's time to kind of look at that and drill down on those kind of questions. Also, the levels of care, Dr Ifejika: it's really important to look at other levels of rehabilitation, so skilled nursing facilities, making sure people have access to that if they need to, if the caregiver is burned out and they don't have the ability to go straight home. Because acute inpatient rehab, the goal of it afterwards, is to go straight home. It's not to go to another facility. So, you need to have that screener in place when it comes to whether the family can take care of this person, and whether the family can do it in an effective way to prevent them being readmitted. Dr Monteith: Great. I also like that you spoke about kind of the team approach and different roles, both for screening and for intervention, both being very important, especially the intervention. And so why don't you give us a few examples how the team could break up the responsibility and how also for the intervention component that can be done. Dr Ifejika: Sure. So, I broke up the team into several levels. So, the team medically is the medical student, resident, and faculty physician. However, the team also includes the support staff, so your case manager, your social worker, the therapist, physical therapy, occupational therapy, speech therapy, the pastoral services, all these members of the team. You know, sometimes as physicians, we don't read those notes. There's a lot of information in the notes from social work, care coordination, and the therapist. They get down to subtleties cause they're asking questions, for example, "What kind of equipment do you have at home? How many stairs do you have at home? What level of house do you have, one story, two story? If you live in an apartment, do you have an elevator access?" That's important for someone with hemiparesis. When it comes to medications, when it comes to insurance status, when it comes to your ability to have the mechanisms to pay for care as an outpatient, social workers are required to ask these questions cause they have to figure out resources for the patient and their family to help facilitate improved outcomes. So, they have to ask questions regarding these tasks. The concerns are, do we read what they're saying? So, it's really important to interact with them, and if it's not something that you're looking at in the chart, cause we're all so tied to our computers, find where they are in the hospital. Walk by their office and have a chat. Run your list with them, especially for people who you're concerned have vulnerabilities, and make sure that you're setting an example for your medical students with your faculty doing so. If you're looking at it from the medical student, resident, faculty perspective, medical students, listen. This is your opportunity to really contribute to the team as well as learn about social determinants of health and research in their fields. You are the boots on the ground for the medical team. You are the ones who should be priming the pump and asking these questions of the family members. We're sending you into the rooms to do a history and physical. Social determinants of health should be a part of your history and physical, and you should be taking what we're saying in this article and asking these questions and tying it into your resident. Now, the resident is the work person of the hospital. We all know this. Things run through the resident. Things run through the fellow. It's really important that they have this information in a manner that is negotiable. The list keeps getting longer, and a resident doesn't need to be overburdened. It needs to be synthesized in a manner that can help facilitate the resident being able to act as well as communicate any concerns to the faculty. And at the faculty level, we are the voices that can affect change. So, if there's any concerns when it comes to advocacy, research, making sure that people are accessing care in a way that makes sense, particularly when it comes to the ability for us to galvanize change on a national level, that's kind of our job. Dr Monteith: Great, and so let's talk about intervention. What are things that, let's say, the neurologist can do to deal with some of these social factors? Dr Ifejika: From the neurology perspective, I think it's really important to identify missed opportunities and making sure that we address them. For example, the conversations around the ability to have access to care related to insurance versus no insurance. There are many, many ways that neurologists are able to advocate for a person being able to get to Medicare insurance, particularly in the outpatient setting. When we see patients in clinic, it takes two years, them, to qualify for Medicare, two years at a minimum. But there's a gap there that can be filled by us making sure that we document what's happened, contact their providers, facilitate communication with their employers, if they're employees, they can get some short-term disability benefits to help bridge that gap prior to receiving Medicare insurance. It behooves us to do this because if we do not, they fall into the gap and they get readmitted and they're back on service anyway. So, what's important is the outpatient that we really kind of focus on things that we can impact and things like insurance and getting people transitioned from having employer-based insurance versus getting to Medicare is a really important way that we can effect change in a, in a way that's viable and, and replicable. So, in the outpatient setting, neurologists have a wonderful opportunity to effect change in social determinants of health. When it comes to employed persons, who had a stroke transitioning to Medicare, it takes two years to do so. So, in the outpatient clinic, if you have an employed person, make sure that you fill out their short-term disability benefits forms, their long-term disability benefits form. Bridge the gap. Get that information to their employer so they can maintain constant coverage. Because if they do not, if they have to choose between refilling medications and putting food on the table, they're going to choose putting food on the table, and that's going to directly impact their outcomes if they're not taking the medication that we recommend. Dr Monteith: I think that's a great point. I mean, there's a lot that we can do, and in some ways, it may not take that much to document and to be able to ask the questions and to include some of that information into the assessment and plan is really a, a great idea. Dr Ifejika: And you know, if we don't bring these things up and have these conversations, it doesn't get addressed. And that's why I'm very, very thankful that I had the opportunity to do so, cause this is a part of what I do all day. I think that if I wasn't integrating these kind of conversations into my practice, I wouldn't have the ability to share these tips and these abilities to move things forward in a manner that will be constructive for our field overall and for our patients. Dr Monteith: And towards the end of the article, you brought up something I think we don't see in many articles, and that's the role of advocacy and getting involved in health policy. So, can you talk a little bit about that? Dr Ifejika: You know, it's really important to facilitate change when you see that there are things that need to be changed. And the best way to do that is through advocacy at the local or state or federal level. A lot of these variables that we're dealing with can be addressed through legal changes. I'll give you an example. End-stage renal disease, if you have immediate hemodialysis and you have that requirement upon hospital discharge, you qualify for Medicare immediately. Immediately. Before you even leave the hospital. Why wouldn't something be similar for a stroke? Well, the reason why is because there was a level of advocacy that came around end-stage renal disease and a member of Congress's wife had hemodialysis requirements. And so, a law was passed to make sure Medicare covered it immediately after hospital discharge. So, it requires advocacy in some significant ways to get things done, but we have the bandwidth to do this. We take care of a population that has some of the highest rates of preventable disability. That's not going away. We need to make sure that we're effecting change for this group to make sure that they have the best possible outcomes they can experience. Dr Monteith: So, any final messages for our listeners? Dr Ifejika: I look forward to hearing everyone's feedback about our issue. I am thankful for the opportunity to talk about, address, and write about this important topic, and look forward to everyone's feedback. Dr Monteith: Well, thank you so much for being on our podcast. It was a really wonderful summary and we had a very thorough conversation, but you didn't give away too much, so I think they're going to have to read the article. Dr Ifejika: You're going to have to read the article. And we want medical students, residents, fellows, faculty, all of our ancillary staff within the hospitals, please read this article. We really appreciate it. Dr Monteith: Again today, I've been interviewing Dr. Nneka Ifejika about her article on social determinants of health and their impacts on stroke prevention and outcomes. This article appears in the June 2026 Continuum issue on cerebrovascular disease. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr. Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

Dr. Garth Nicolson, Founder, President, Chief Scientific Officer, and Emeritus Research Professor of Molecular Pathology at the Institute for Molecular Medicine in Huntington Beach, California, and Research Advisor for Nutritional Therapeutics, explains how membrane damage from free radicals and loss of mitochondrial transmembrane potential contribute to declining energy with age, noting studies in older adults showing improved energy output, fatigue, cognition, mood, and activity after NTFactor lipids, a protected phospholipid supplement balanced toward mitochondrial lipid composition. He describes evidence of lipid delivery using fluorescent-tagged lipids in sperm, with improved motility, and discusses applications including wound healing in veterans, removal of hydrophobic toxins via a concentration-driven “conveyor belt” process, and improved transport of nutrients like CoQ10. He details articles on normal aging, menopause-related changes supported by membranes, dementia risk linked to hearing loss, and rat studies showing delayed hearing loss with NTFactor, and mentions research on EMF sensitivity and planned schizophrenia trials.

Dr. Hoffman continues his conversation with Dr. Garth Nicolson, Founder, President, Chief Scientific Officer, and Emeritus Research Professor of Molecular Pathology at the Institute for Molecular Medicine in Huntington Beach, California, and Research Advisor for Nutritional Therapeutics.

We love to hear from our listeners. Send us a message.In episode 2 of this four-part in vivo-focused special series of Cell & Gene: The Podcast, Host Erin Harris sits down with Gopi Shanker, Ph.D., Chief Scientific Officer at Beam Therapeutics, for an in-depth conversation on the rapidly evolving landscape of in vivo gene editing and precision genetic medicines. Dr. Shanker discusses how next-generation base editing technologies are advancing beyond traditional CRISPR approaches by enabling precise single-base changes without creating double-stranded DNA breaks. They discuss the growing momentum behind in vivo delivery strategies, including targeted LNP technologies designed to reach tissues beyond the liver, as well as the operational and patient-centric advantages these approaches may offer compared to ex vivo therapies. Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

Could mushrooms hold the secret to better gut health, lower cholesterol, and can they protect your brain? Today, Professor Robin May, a leading microbiologist and the UK Government's Chief Scientific Officer, explores why our interest in mushrooms has exploded. He explains why they are not just another vegetable but could hold the key to better gut health, brain health, immune health, and lower cholesterol. By the end of the episode, you'll know which health claims about mushrooms are real, which are exaggerated and where the science is just too early to trust. You'll have a solid understanding of what mushrooms are really doing inside our bodies and how to unlock the secret health powers they hold. Should mushrooms become a regular part of your weekly shop rather than an occasional side dish? And if fungi have evolved alongside humans for millions of years, what else might they reveal about the future of nutrition and health?

This interview is disseminated on behalf of Conexeu Sciences Inc.Reconstruction is being redefined with Conexeu Sciences Inc. (NASDAQ: CNXU), as the company recently announced the development of Bio-Regenerative Ergonomically Architected Smart Tissue™ (B.R.E.A.S.T.™), a new approach designed to advance breast reconstruction following mastectomy.In this exclusive interview, Chief Scientific Officer and Co-Founder Dr. Claudia Chavez-Munoz, MD, PhD, outlines the science behind the program, its mechanism of action, and how the company is leveraging its proprietary CXU™ platform to expand across multiple applications.Watch now to find out how B.R.E.A.S.T.™ is designed to potentially help the body rebuild itself.Learn more: https://www.conexeu.com/Watch the full YouTube interview here: https://youtu.be/N8thuQMx6Z8And follow us to stay updated: https://www.youtube.com/GlobalOneMedia 

Alisha Holloway is the Chief Scientific Officer at Phylos where she leads the R&D group that focuses on foundational genomic research, development of high-throughput genetic and chemical testing capabilities, discovery of genetic markers, and the development of new cannabis varieties via classical and marker-assisted breeding. At CannMed 26, she will present “Enhancing Cannabis Quality via Marker-Assisted Selection for Improved Solventless Extraction Yield” During our conversation, we discuss: What solventless extraction is and why it’s gaining popularity The traits that make a cannabis plant a “good washer” How Alisha's team designed and conducted a washability study across hundreds of plant samples How they identified genetic markers for good washers that hold up across diverse genetic backgrounds How marker-assisted selection accelerates the breeding process Thanks to This Episode’s Sponsor: The Cannabis Research Center & Coalition The Cannabis Research Center & Coalition (CRC), founded by Dr. Allison Justice, is a professional group dedicated to advancing cannabis cultivation and post harvest processing. CRC partners with Universities and The Hemp Mine LLC, an industry leader in cannabis genetics and production, to tackle the cultivation and post harvest challenges facing today's cannabis industry. Their cooperative research model, inspired by successful horticulture and greenhouse research collaborations, allows members to benefit from pooled resources, gaining access to cutting-edge, science-based research at a fraction of the cost. Learn more at cannabisrc.org Additional Resources Phylos.bio, Instagram, Linkedin [Blog] What Makes a Cannabis Variety “Wash Well”? The Science Behind High-Yield Hash Plants https://www.instagram.com/shwale/ Register for CannMed 26 Meet the CannMed 26 Speakers Review the Podcast CannMed Archive

We review the racing from the WTCS event in Alghero, IRONMAN Brazil and Challenge St Poelten. The Enhanced Games – what are the implications for clean sport and athlete integrity. Professor Alison Heather, Chief Scientific Officer at Insitugen, updates us on the evolution of anti-doping and the implications of new anti-doping and testing technologies. TIMESTAMPS 0:00:00 – Kate and Guy in Malaysia this week 0:01:07 – The Timber Trail 0:05:52 – WTCS Alghero race review 0:18:02 – IRONMAN Brazil 0:22:14 – Should IRONMAN standardise pay across all events 0:23:55 – Challenge St Poulton race review 0:25:45 – The Enhanced Games 0:34:22 – Testosterone clinics in NZ 0:36:13 – Professor Alison Heather intro 0:37:06 – Alison Heather on testosterone 0:40:00 – Jack Moody's testing 0:44:45 – Alison Heather on how far anti-doping has come 0:48:02 – How do we avoid contamination 0:58:22 – Alison Heather shares her thoughts on publicizing results LINKS: Jack Moody at https://www.instagram.com/jacktmoody/ Kate Bevilaqua at https://www.instagram.com/katebevilaqua/ Guy Crawford at https://www.instagram.com/guyrcrawford/ The Timber Trail at https://www.timbertrail.nz/ The Whaka 100 at https://www.whaka100.co.nz/ WTCS event Alghero at https://events.triathlon.org/2026-wtcs-alghero Challenge St Poelten at https://challenge-stpoelten.com/ IRONMAN Brazil at https://www.ironman.com/races/im-brazil The Enhanced Games at https://www.enhanced.com/ Professor Alison Heather at https://insitugen.com/about-us/

“Behind every breakthrough are countless failures no one ever sees—but that's exactly what makes progress possible.” Dr. Thomas Kaiser. When I have scientists on the podcast: they're some of the coolest, smartest, funniest people, and they're always willing (and excited) to explain what they do in ways you can actually understand. Dr. Tom Kaiser is no exception. He lives and works in Durham, North Carolina, and brings together an impressive mix of scientist, physician, and entrepreneur. His work focuses on designing better medicines using cutting-edge technology. He began his career at Emory University in Dennis Liotta's lab, working on antiviral drug discovery, and later helped pioneer early machine learning approaches in drug design. His research spans RSV, cancer, and neurodegenerative diseases, and he went on to earn his medical degree from the University of Oxford. Tom is now the co-founder and Chief Scientific Officer of Avicenna Biosciences, where he's leading the development of innovative therapies aimed at improving and saving lives. And my favorite detail from his bio? He ends it by mentioning the love of his life, his wife. I'll be honest, when I first met him, I told Dr. Kaiser he seemed like someone who must have been in a movie. He's just that cool. His Company: Dr. Thomas Kaiser shares the story behind his company's name, Ibn Sina, also known as Avicenna a true Renaissance figure of the Islamic Golden Age. A physician, philosopher, and scientist, Ibn Sina embodied the kind of multidisciplinary thinking that still drives innovation today. It's a powerful reminder that the roots of modern medicine, and the spirit of discovery stretch back centuries. The Part We Don't Talk About Enough Science is not a straight line. Not even close. Experiments fail. Clinical trials don't work. Hypotheses fall apart after years of effort. Funding can disappear. Progress can stall in ways that are frustrating and sometimes heartbreaking especially when patients are waiting. Dr. Kaiser speaks about this with a clarity and calm that really stayed with me. Because the truth is: scientists have to keep going anyway. They carry the weight of those disappointments and start again. They adjust, rethink, rebuild, and try again. Over and over. And that persistence? That's where breakthroughs come from. From the outside, it's easy to celebrate the wins ... the new drug, the successful trial, the headlines. But behind every one of those moments are countless failures no one ever sees. For families like ours, waiting, hoping, advocating it matters to understand that this difficult process is also what makes progress possible. Living the Dream What if you actually got to live the dream you had as a kid? In this conversation, Dr. Thomas Kaiser shares something surprisingly personal: he feels lucky to be doing exactly what he dreamed of as a child. That early curiosity grew into a career designing new medicines and pushing the boundaries of science. From imagination to impact, his journey is a reminder that sometimes those childhood passions really can shape the future. Go to Dr. Kaisers website:  https://www.avicenna-bio.com Like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredNew: Shop our merchandise! https://thebonnellfoundation.org/product-shop/Thanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

Du schläfst ausreichend und fühlst dich trotzdem dauerhaft erschöpft? Woran liegt das? Wir gehen dem auf den Grund!In dieser Folge der Flowgrade Show spreche ich mit Dr. Wolfgang Brysch über die wahre Grundlage von Gesundheit, Leistungsfähigkeit und Langlebigkeit: biologische Energie.Wir tauchen tief in die Welt der Mitochondrien ein, sprechen über die größten Energieräuber unserer modernen Gesellschaft und darüber, warum immer mehr Menschen trotz optimierter Ernährung, Nahrungsergänzung und Schlaf das Gefühl haben, ständig „auf Reserve“ zu laufen.Dr. Brysch erklärt, warum Energie auf zellulärer Ebene entsteht, welche Rolle unser Gehirn dabei spielt und weshalb Faktoren wie künstliches Licht, Bewegungsmangel, Stress und Reizüberflutung unseren Energiestoffwechsel stärker beeinflussen als vielen bewusst ist.Außerdem sprechen wir darüber, warum die Qualität von Mikronährstoffen entscheidend ist, weshalb Bioverfügbarkeit oft wichtiger ist als die reine Dosierung und warum Gesundheit nicht durch einzelne Wundermittel entsteht, sondern durch das Zusammenspiel vieler Faktoren.In dieser Episode erfährst du:• warum so viele Menschen chronisch erschöpft sind• welche Rolle Mitochondrien für deine Energie spielen• warum das Gehirn zu den größten Energieverbrauchern gehört• die größten Energieräuber unseres modernen Lebens• weshalb künstliches Licht unseren Stoffwechsel beeinflusst• warum Bewegung ein zentraler Energielieferant ist• wie Mikronährstoffe tatsächlich wirken• weshalb Bioverfügbarkeit oft unterschätzt wird• was freie Radikale wirklich sind• wie du deine Energie nachhaltig verbessern kannstEine spannende Folge für alle, die ihre Gesundheit, Leistungsfähigkeit und Lebensqualität langfristig verbessern möchten.Viel Spaß beim ZuhörenGo for Flow

“What if the exhaustion, brain fog, low libido, and metabolic changes women experience in midlife are actually rooted in a deeper cellular energy crisis?” In this episode, Dr. Mariza sits down with Dr. Andrew Salzman — physician, inventor, biochemical engineer, and Chief Scientific Officer of Wonderfeel — to unpack the powerful connection between NAD, mitochondrial health, inflammation, ovarian aging, gut integrity, nitric oxide, and the dramatic energy shifts women experience during perimenopause and menopause. Dr. Salzman explains why menopause represents a major biological inflection point for women and how declining NAD levels may be contributing to fatigue, brain fog, poor recovery, metabolic dysfunction, sleep issues, reduced stress resilience, cardiovascular changes, and shifts in sexual health. Together, they explore the evolutionary role of menopause, why ovarian senescence accelerates aging pathways, how inflammation and the enzyme CD38 rapidly deplete NAD stores, and why the gut microbiome may be one of the biggest drivers of inflammation and energy decline in modern women. They also dive into nitric oxide production, cardiovascular health, the brain's dependence on NAD for sleep and cognitive function, and why ingredients like NMN and creatine are gaining attention for supporting healthy aging and resilience in midlife. If you've ever looked in the mirror and thought, “I don't feel like myself anymore,” this conversation will help connect the dots between your symptoms, your mitochondria, and your long-term vitality. ANDREW SALZMAN Dr. Andrew Salzman is a physician, inventor, biochemical engineer, and the Chief Scientific Officer of Wonderfeel. With more than 30 years of experience in drug discovery and development, over 170 scientific publications, and more than 50 patents, Dr. Salzman has spent decades studying aging biology, inflammation, cellular resilience, nitric oxide signaling, and mitochondrial health IN THIS EPISODE Why menopause is a major biological inflection point for women How declining NAD levels impact energy, metabolism, sleep, and brain function Why CD38 accelerates inflammation and NAD depletion during aging The surprising connection between gut health, inflammation, and menopause symptoms How estrogen decline contributes to leaky gut and systemic inflammation Why nitric oxide is essential for circulation, libido, cardiovascular health, and cognition The role of NAD in circadian rhythm, sleep quality, and stress resilience Why NMN and creatine are gaining attention for healthy aging and vitality QUOTES“Menopause will happen, but the question is: how do we maintain vibrancy and resilience through it?” “NAD is the common currency that drives energy throughout the body.” “The gut is the foundational driver of inflammation as we age.” “Without NADPH, you don't have nitric oxide production.” RESOURCES MENTIONED Subscribe and Save $15 on Wonderfeel Youngr™ NMN: https://tidd.ly/4rPnckS Use code ENERGIZED and get 30% off on your first BATCH order https://hellobatch.com/ENERGIZED Order my newest book: The Perimenopause Revolution https://peri-revolution.com/ Wonderfeel Website Wonderfeel Instagram Wonderfeel YouTube RELATED EPISODES  741: Estrogen, Gut Health, Mitochondria, and Cardiovascular Health: What Changes In Perimenopause with Dr. Siobhan Mitchel 691: The Fertility Crisis No One Talks About: Why Your Health Today Impacts Future Generations with Dr. Ann Shippy 717: “I Don't Feel Like Myself Anymore”: The Mental & Emotional Reality of Perimenopause 743: Why Your Heart Risk Changes in Menopause (And What You Can Do About It) with Dr. Jayne Morgan

Is it ok to store food in plastic containers?That's the question put by listener Joe Tattersall in this, the last episode in the current series of 'Sliced Bread'. Joe's noticed scuffs and abrasions on his reusable plastic containers and is concerned about whether that increases the risk of 'chemical leaching' into his food, or ingesting microplastics. He's keen to know if alternatives like glass, silicon, or metal containers could better for our health, as well as for the planet.And what about putting them in the microwave to heat food, using them to freeze food after batch-cooking, or putting them in the dishwasher to clean? To find out more, presenter Greg Foot is joined by Dr Stephanie Wright, Senior Lecturer in Environmental Toxicology at Imperial College London; and Jane Muncke, Managing Director and Chief Scientific Officer at the Food Packaging Forum.We're taking a break to prepare another batch of Sliced Bread but we're as hungry as ever for your suggestions of wonder products to investigate. Please do send your ideas to us either on email to sliced.bread@bbc.co.uk or to our WhatsApp number, 07543 306807.RESEARCHER: PHIL SANSOM PRODUCERS: SIMON HOBAN AND GREG FOOT

Is it ok to store food in plastic containers?That's the question put by listener Joe Tattersall in this, the last episode in the current series of 'Sliced Bread'. Joe's noticed scuffs and abrasions on his reusable plastic containers and is concerned about whether that increases the risk of 'chemical leaching' into his food, or ingesting microplastics. He's keen to know if alternatives like glass, silicon, or metal containers could better for our health, as well as for the planet.And what about putting them in the microwave to heat food, using them to freeze food after batch-cooking, or putting them in the dishwasher to clean? To find out more, presenter Greg Foot is joined by Dr Stephanie Wright, Senior Lecturer in Environmental Toxicology at Imperial College London; and Jane Muncke, Managing Director and Chief Scientific Officer at the Food Packaging Forum.We're taking a break to prepare another batch of Sliced Bread but we're as hungry as ever for your suggestions of wonder products to investigate. Please do send your ideas to us either on email to sliced.bread@bbc.co.uk or to our WhatsApp number, 07543 306807.RESEARCHER: PHIL SANSOM PRODUCERS: SIMON HOBAN AND GREG FOOT

Day Break | Peace, War, and the Cost of Democrat Promises --- 00:00 - Monologue 19:05 – Grover Norquist, President of Americans for Tax Reform. Norquist discusses a proposed federal vehicle registration tax targeting electric vehicles and plug-in hybrids. He explains concerns that the plan could expand into a broader national vehicle tax while turning state DMVs into federal tax collection agencies. The conversation focuses on transportation costs, taxation, and government overreach affecting American drivers. 27:57 – Dr. Peter A. McCullough, MD, MPH, Chief Scientific Officer at The Wellness Company. Dr. McCullough discusses recent media attention surrounding Ebola and Hantavirus outbreaks. He explains the origins and transmission concerns tied to Ebola, screening procedures for incoming international flights, and questions surrounding long-term transmissibility of Hantavirus. He also shares preparedness recommendations for viewers concerned about emerging health threats. Visit twc.health/GRUBER and use promo code GRUBER to save. 38:09 - Monologue Featuring Ivey Gruber 57:17 – Scott Rasmussen, pollster, ESPN co-founder, and author of Out of Touch: The Elite One Percent and the Battle for America's Soul. Rasmussen discusses public distrust of political elites and polling data suggesting many Americans believe members of the political class would cheat to win elections or maintain power. 1:06:14 – Brian A. Rankin, Adjunct Fellow at the Competitive Enterprise Institute and telecommunications attorney. Rankin discusses the growth of wireless technology, the importance of unlicensed spectrum, and how innovations like Wi-Fi have transformed communications, business, and everyday life. 1:16:20 - Monologue 1:25:08 – Ron Rademacher, travel writer, author, speaker, and storyteller. Rademacher shares events happening around Michigan and highlights destinations, festivals, and outdoor activities taking place across the state. 1:35:14 – Dr. Matthew Mehan, educator and author of The American Book of Fables. Mehan discusses his new book and the importance of moral storytelling, civic education, and passing down foundational values through literature and fables. 1:44:06 – Ivey Gruber, President of the Michigan Talk Network. Gruber reflects on the beauty of America's national parks and the value of travel and exploration. The conversation highlights personal travel experiences and the importance of appreciating the country's natural wonders. --- Check out our brand new podcast, 'Forgotten America'... Episode 16 is live NOW at Steve Gruber on YouTube! Link below: https://youtu.be/I4UA2LzQQUg  

What does it really take to progress from bench science to leading a Biotech platform as Chief Scientific Officer? In this episode of Careers in Discovery, Daniel Tardiff, CSO at Camp4 Therapeutics, shares a candid look at building and scaling science inside an early‑stage biotech. From his foundations in RNA biology to advancing antisense programmes for haploinsufficiency-driven neurodevelopmental disorders, Dan unpacks how translational judgement is developed over time, not taught. Key takeaway: Career progression isn't about having perfect answers. It's about making credible decisions under uncertainty and bringing others with you as the science scales.

Brady Carter, Ph.D. is the Chief Scientific Officer at Carter Scientific Solutions. He specializes in water activity, moisture sorption, shelf-life stability, plant science, and wheat production and quality. He has 23 years of experience in research and development and previously was a Research Professor at Washington State University focusing on wheat end-use quality. Dr. Carter has pioneered work in using dynamic isotherms to investigate product stability and establish critical water activities for optimal shelf life. He also specializes in shelf-life loss and effective utilization of instrumentation to address product safety and quality issues. Dr. Carter holds a Ph.D. in Crop Science and Food Engineering and an M.S degree in Cereal Chemistry and Crop Science from Washington State University, as well as a B.A. degree in Botany from Weber State University. In this episode of Food Safety Matters, we speak with Dr. Carter [41:18] about: The basics of water activity, including how it is measured and how it differs from moisture content The influence of water activity on food safety and shelf life, and how water activity data can support the validation of shelf-life claims Ways manufacturers can incorporate water activity into their shelf-life and food safety testing, and during research and development when formulating products Regulatory expectations around water activity monitoring as part of validation and verification The realities of water activity measurement that make real-time, inline testing impractical with current technology How water activity monitoring can help mitigate food waste The importance of the statement, "water activity is the energy of water." News and Resources News Donald Prater Becomes New Head of FDA Human Foods Program [16:54]FDA Commissioner Steps Down, To Be Replaced by Agency's Human Foods LeaderTop U.S. Food Safety Officials Discuss Regulatory Landscape at Food Safety Summit FDA Encourages Industry to Develop Best Practices, Use Root Cause Analyses [20:30] FDA Finalizes Systematic Post-Market Food Chemical Review Process [21:34] FDA Launches One-Day Inspectional Assessments [22:30] Scientists Tackle Food Waste with More Accurate 'Sell By' Dates Based on Meat Microbial Activity [27:42] Monitoring Data Show EU Food Mostly Compliant with Pesticide Limits [35:58] Resources Food Safety Rockstar T-Shirts on Amazon (BE ADVISED: they run small) We Want to Hear from You! Please send us your questions and suggestions to podcast@food-safety.com

Marco Quarta is co-founder and Chief Scientific Officer of Rubedo Life Sciences, a precision-therapeutics company developing medicines that target the pathological cell states that drive age-associated disease. Marco's first appearance on the show was three years ago, in February 2023 (Episode 35), when Rubedo was a much earlier-stage company committed to the then-contrarian premise that "the senescent cell" is not a single entity but a heterogeneous family of cell states that needs to be deconvoluted at the single-cell level. In March 2026, Rubedo reported preliminary Phase 1b/2a clinical data for its lead candidate, RLS-1496, a first-in-class topical GPX4 modulator. Marco returns to the show to discuss what survived contact with human biology.In this episode, Chris and Marco unpack the readout from Rubedo's basket trial across four skin indications — psoriasis, atopic dermatitis, actinic keratosis, and photoaged skin — and the biology that underlies it. RLS-1496 came clean on safety in all four indications, with significant efficacy signals despite small patient numbers and short (20–30 day) treatment courses. More provocatively, the clinical and translational data have pushed Marco to redefine what kind of drug this actually is. Rather than a next-generation senolytic, GPX4 modulation appears to act as a state-gating intervention: it triggers ferroptosis in deeply senescent cells that have already crossed a redox threshold, while inducing a hormetic "redox reset" in stressed-but-recoverable cells that restores them to a healthier state. Marco proposes a new category to capture this dual action — adaptive senotherapeutics, or senoadaptive drugs — distinct from senolytics and senomorphics.The conversation traces the arc from Rubedo's founding thesis to a clinically validated platform (ALEMBIC, the AI-enabled single-cell multiomics engine that surfaced GPX4 as a target), through the strategic logic of leading with skin, into the broader question every longevity-biotech founder eventually has to answer: when does a disease-by-disease franchise become a credible preventive geroscience platform? Marco lays out the GLP-1 analogy explicitly — an anchor indication and a label-expansion roadmap that could carry GPX4 modulation from dermatology into respiratory, neurodegenerative, and metabolic disease, and ultimately into the use case where biomarkers of cellular senescence flag patients for therapy decades before disease becomes clinically apparent.The Finer Details:How Marco's 2023 contrarian view — that "senescent cells" hide a tissue- and state-specific reality — has been reinforced by the clinic, and how Rubedo's framing has shifted from "targeting senescent cells" to "targeting pathological cell states"The biology of GPX4 as a lipid-peroxidation gatekeeper, why senescent cells have intrinsic vulnerabilities (p16, p21, CDK4/6 inhibition) that make them ferroptosis-sensitive, and how Rubedo's approach differs from oncology-focused GPX4 programs at Takeda and othersThe "senoadaptive" mechanism — RLS-1496 eliminates GPX4-dependent senescent cells via ferroptosis while triggering NRF2/Keap1-driven redox reset, autophagy, and epigenetic remodeling in recoverable cells, restoring tissue trajectory from degenerative to regenerativeWhy Rubedo led with skin: clean regulatory path, accessible tissue, the ability to read out aging biology anddisease in the same trial, and a label-expansion runway into systemic indicationsPhase 1b (Europe) and Phase 2a (US) basket-trial results across psoriasis, atopic dermatitis, photoaged skin, and actinic keratosis: clean safety in 4/4 indications and significant efficacy signals — itch reduction in atopic dermatitis, decreased lesional thickness in psoriasis, target-engagement-correlated clinical improvement in photoaged skinThe richness of the translational dataset: biopsies, tape-stripping, spatial transcriptomics, proteomics, multiplex histomics, plasma biomarkers — all feeding back into ALEMBIC to refine the platformWhy actinic keratosis is the most strategically important indication — an age-related, chronic-inflammatory, precancerous condition where Rubedo can simultaneously test disease modification and biological-age reversalThe Rubedo–Beiersdorf partnership and the cosmetic vertical as a parallel commercial axisPipeline beyond skin: targeting aberrant basaloid stem cells in IPF and other pulmonary indications using different modalities (prodrugs, PROTACs, ADCs) to achieve cell-state selectivityThe longer-arc vision: senescence biomarkers as a "prediabetes-style" early signal, with senoadaptive drugs deployed decades before disease — and what a GLP-1-scale franchise might look like for GPX4 modulationQuotes:"There is not such a thing as a senescent cell — like there is not a cancer cell. And that was the initial idea. I'm glad that over time the field evolved. Now this is an accepted concept in the senotherapeutic space.""We are really talking about a dual function of RLS-1496 that can modulate the cell state depending on the adaptive response. That's why we call this — de facto — a new class of senotherapeutics. We call them adaptive senotherapeutics, or senoadaptive drugs — not a senolytic or a senomorphic, but working by modulating the cell state.""The best animal model for human therapies is human. As much as you can do preclinical work in animal models, it's always an approximation. We were able to test this directly in patients for safety, and in 4 out of 4 indications, we didn't have any safety signal.""Imagine you're taking care of a growing tree, and this tree has some dead leaves and some are a little bit stressed. If you shake the tree, the dead leaves will fall; the healthy leaves will not, because they're healthy and they resist the shake. But that shake actually gives the stressed leaves space and breathing room, and helps them to regain vitality. That's a little bit what GPX4 modulation does.""Senotherapeutics is a large, growing field — an untapped therapeutic opportunity. There is no such thing as a pan-senolytic or a pan-senotherapeutic, like there is no pan-oncotherapeutic. You need to understand the context. But these will all be part of the arsenal for true longevity medicine.""I don't see this as prevention of disease. The way I see therapies like ours, and the way the field of longevity is developing, is treating diseases decades before they develop. That's not a new concept — that's what we're doing in diabetes. You can be diagnosed with prediabetes today and reverse those biomarkers with lifestyle changes or metformin, and maybe never develop diabetes. That's exactly what we're doing here.""First of all, celebrating the first approved drugs from Rubedo — I don't think we're too far from that. But that's also a beginning, because you learn from the big momentum the GLP-1 agonists created: how a drug can start in one indication, create a new field, and prove that you can go beyond that. I hope in a few years we come back and talk about the next GLP-1 — this could be GPX4 modulators, or the senoadaptive drugs that are first in our pipeline."Links:Rubedo Life Sciences: https://www.rubedolife.comMarco Quarta's previous appearance on Translating Aging: Ep 35 — Targeting Pathologic Cells to Preserve Biological Youth

Kati Devaney is a neuroscientist and meditation teacher with over 25 years of practice. She earned her PhD in 2018 using fMRI to study attention and prediction updating in experienced Vipassana meditators and completed a postdoc at Harvard Medical School. She's now the Chief Scientific Officer at the Consciousness Foundation, co-founded the Berkeley Alembic and the SF Dharma Collective, advises Jhourney on the neuroscience of jhana, and has been quoted on the brain and meditation in The Atlantic, National Geographic, and TIME.In this episode we talk about weird stuff like cessation, jhanas, and non-duality. We also explore how the brain quietly constructs your sense of reality moment-to-moment, and how to (re)start a meditation practice. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit themetagame.substack.com

Dr. Fiona Lovely welcomes back Dr. Siobhan Mitchell, Chief Scientific Officer of MitoQ and an expert in nutritional neuroscience, for a conversation that digs deeper into the metabolic shifts women experience at midlife. Dr. Mitchell explains how declining estrogen directly impacts mitochondrial health, which in turn affects everything from energy levels and muscle strength to where the body stores fat. Listeners will learn why the same diet and exercise routines may stop working during perimenopause, and why that stubborn belly fat is not a personal failure but a biological response to changing hormones. Dr. Mitchell discusses the protective role of estrogen, the emerging understanding of the estrobolome, and practical options for support including HRT, phytoestrogens from sources like soy, and the lesser-known compound S-equol. She also shares what she wishes she had known earlier about stress and risk-taking, offering a personal insight that may resonate with many listeners navigating midlife changes.   Episode Highlights: How declining estrogen leads to reduced mitochondrial function, affecting energy, muscle strength, and inflammation throughout the body Why women gain visceral belly fat during perimenopause even when diet and exercise have not changed How the estrobolome, or gut bacteria responsible for recycling estrogen, can be supported to improve metabolic outcomes The role of phytoestrogens and S-equol, including why only about twenty percent of Western women can produce this beneficial compound naturally How HRT, phytoestrogens, and targeted supplements can work together or separately to support women through the menopausal transition This episode offers a clear roadmap for women who want to understand what is happening inside their bodies and take informed steps toward maintaining their health through the menopausal transition.    Thank you to our sponsors for this episode: The transition through midlife often brings a frustrating trio of shifts: the stubborn bloating, those unpredictable energy swings, and changes to the midsection that feel completely outside of your control. Harnessing the power of S-Equol, B. breve, and chromium, this formula is uniquely designed to support healthy estrogen signaling and metabolic function. It's about more than just numbers; it's about stabilizing blood sugar, restoring gut comfort, and supporting a healthy body composition so you can feel like yourself again. Go to www.mitoq.com and use code LOVELY10 for 10% off your first order! If night sweats and restless sleep are disrupting your rest, Cozy Earth's bamboo sheets and pajama sets are temperature-regulating and moisture-wicking — designed to sleep several degrees cooler than cotton. Because supporting your body through menopause starts with how you sleep. Visit cozyearth.com and use code LOVELY for 20% off.   Dr. Fiona Lovely is a longevity, health and wellness expert with specialties in menopause medicine, functional neurology and functional medicine.  She is speaking to the topics of women's health around perimenopause and menopause. How to work with Dr. Lovely: We get many requests for this info, so here it is!  First off, thank you for listening to the NYMM podcast.  It's because of your support, we can continue to dispense this information.❤️ Follow Dr. Lovely on IG and TikTok: @drfionalovely Follow the podcast on Facebook:  www.facebook.com/@notyourmothersmenopausepodcast Please sign up for our newsletter - Fiona's Friday Favourites!  This is where we make the first announcements, share course offerings, drop new episodes,  blog posts and the coveted 'Fiona's Favourites' column, etc.   drlovely.com You can also find some great resources there! Finally, a humble request:  If you love the podcast, please leave us a review!  It helps more people find useful info for a challenging time: https://podcasts.apple.com/ca/podcast/not-your-mothers-menopause-with-dr-fiona-lovely/id1097326296  Please scroll to the bottom of the page to leave a review.  Thank you! 

In this episode, I sit down with Dr. Luke R. Bucci, Chief Scientific Officer of Juvenon and a biomedical scientist, to reframe what healthy aging actually means. We break it down to two core pillars: circulation and metabolism. Because if your body can't efficiently deliver oxygen and nutrients, or convert them into usable energy, everything downstream is affected. We explore why blood flow is often overlooked, yet critical to cellular health, cognition, and recovery, and how metabolic function goes far beyond weight loss, influencing energy, repair, and overall performance. Dr. Bucci also challenges some of the current trends in longevity, including the hype around certain supplements, and emphasizes the importance of foundational physiology over quick fixes. We also touch on joint health, discussing compounds like glucosamine, chondroitin, and krill oil, and how they continue to play a role in long-term structural support. If you want to better understand what's really driving aging—and how to support it at a cellular level—this episode will shift your perspective.   Key takeaways: Glucosamine and chondroitin remain essential for joint health, working together to nourish cartilage and boost the body's natural repair processes. Circulation and nitric oxide production are key factors in aging, with Dr. Bucci noting a significant decline in these areas as early as age fifty. Dr. Bucci raises concerns over NAD supplements, suggesting they may have unrecognized cardiotoxic effects when consumed in high amounts. Proper metabolism is interdependent with good circulation, highlighting the importance of efficient energy conversion to reduce age-related symptoms. Dr. Bucci strongly advocates for foundational lifestyle habits such as exercise, targeted supplementation, and a balanced diet as cornerstones of healthy aging.   More About Dr. Luke Bucci: Dr. Luke R. Bucci, PhD, CNS-S, CCN (Ret.) is the Chief Scientific Officer of Juvenon and a biomedical scientist with more than 40 years of experience in nutrition, dietary supplements, and clinical laboratory science. He earned his PhD in Biomedical Sciences from the University of Texas Health Science Center at Houston and was among the first Certified Clinical Nutrition Specialists (CNS) and Certified Clinical Nutritionists (CCN), helping establish national competency standards in clinical nutrition certification. A respected authority in joint health, sports nutrition, women's health, probiotics, omega-3s, adaptogens, hormones, and regulatory science, Dr. Bucci has also authored scientific books and taught university-level courses on dietary supplement regulations. He is the recipient of the James Lind Scientific Achievement Award and the Supplement Industry Icon for Science & Innovation Award.   Website Instagram Connect with me! Website Instagram Facebook YouTube

You can stack every supplement, peptide, and biohack out there. It still won't fix the one thing wearing most of us down faster than any of it: unresolved stress and trauma.Dr. Bhargav Patel has spent his career studying how that wear and tear shows up in the brain, the body, and the lifespan, none of which a standard lab test will flag. He's one of the few doctors who treat the mind as part of the body rather than something separate from it.He walks us through the framework behind trauma recovery, why SSRIs work for reasons most people get wrong, and how processing trauma can hit 75% recovery rates. AI in healthcare comes up, too, along with why hallucinations are baked into every LLM and just how wide the mental health access gap is in the U.S."Supplements aren't the core of your longevity regimen. They're the last 5 to 10%. The 90% is the core health things we all know we should do: exercise, sleep, and eat well." ~ Dr. Bhargav PatelSupport the show and get 50% off MCT oil with free shipping—just leave us a review on iTunes and Spotify and let us know! https://podcasts.apple.com/us/podcast/live-beyond-the-norms/id1714886566Resources MentionedThe Body Keeps the Score by Bessel van der Kolk: https://www.penguinrandomhouse.com/books/313183/the-body-keeps-the-score-by-bessel-van-der-kolk-md/The Hypomanic Edge by John D. Gartner: https://www.simonandschuster.com/books/The-Hypomanic-Edge/John-D-Gartner/9780743243452MyPEAK Supplements: https://www.mypeaksupplements.com/ About Bhargav PatelDr. Bhargav Patel is a board-certified psychiatrist and NIMH-funded Child and Adolescent Psychiatry research fellow at Brown University. He's the founder of Sage Psychiatric Professionals and serves as Founding Medical Director and Director of AI Decision Support at Sully.ai. He's also the Co-Founder, CEO, and Chief Scientific Officer of MyPEAK. His upcoming book, Trauma Transformed, looks at how the brain actually heals from trauma, and what most of us get wrong about the process.Connect with Bhargav PatelWebsite: https://www.bhargavpatelmd.com/ LinkedIn: https://www.linkedin.com/in/bhargav-b-patel Newsletter: https://bhargavpatelmd.beehiiv.com/ Connect with Chris Burres Website: https://www.myvitalc.com/ Website: http://www.livebeyondthenorms.com/ Instagram: https://www.instagram.com/chrisburres/ TikTok: https://www.tiktok.com/@myvitalc LinkedIn: https://www.linkedin.com/in/chrisburresDisclaimerThe content shared in this podcast is intended for educational and informational purposes only. It does not constitute medical advice of any kind, nor does it include any specific claims or guarantees. The views expressed are based on personal experiences, research, and individual perspectives, and are meant to inspire and inform listeners on topics related to wellness, lifestyle, and personal development.

In this episode of Careers in Discovery, Adrian Gabriel Torres, Chief Scientific Officer at Aptadel Therapeutics, talks about developing RNA aptamer–based cancer therapies and leading scientific strategy in a preclinical biotech start-up. Adrian also shares his journey from academic research into industry, reflecting on the differences between academia and biotech, learning new skill sets, managing teams, and making career decisions along the way.

Algae is often overlooked, but it may be one of the most powerful tools for supporting energy, detoxification, and cellular health. In this episode, Dr. Jen sits down with Catharine Arnston, PhD, founder of ENERGYbits, to unpack the science behind spirulina and chlorella and why these ancient organisms are gaining attention in modern health. They explore how algae supports mitochondrial function, reduces oxidative stress through compounds like superoxide dismutase (SOD), and helps the body manage toxins and nutrient deficiencies. Catharine also explains the key differences between spirulina and chlorella, how each impacts the body, and how to incorporate algae into a daily routine for sustained energy, metabolic resilience, and long-term wellness.Catharine Arnston, PhD, is the Founder, CEO, and Chief Scientific Officer of ENERGYbits, a premium algae nutrition company. After a 25-year corporate career, she pivoted into health and wellness following her sister's breast cancer diagnosis, which led her to discover the powerful benefits of algae. Now a Board-Certified Health Coach with a PhD in Natural Health, Catharine has spent nearly two decades researching spirulina and chlorella and their impact on mitochondrial health, oxidative stress, and longevity. She is a leading voice in algae nutrition and a frequent guest on top health podcasts.Website: https://energybits.comInstagram: https://www.instagram.com/catharinearnstonLinkedIn: https://www.linkedin.com/in/catharinearnstonYouTube: https://www.youtube.com/energybitsThis episode is brought to you by Energy Bits. Visit www.energybits.com and use the code DRJEN to get 20% off your purchase.PODCAST: Thank you for listening please subscribe and share! Shop supplements: https://healthybydrjen.shop/CHECK OUT a list of my Favorite products here: https://www.healthybydrjen.com/drjenfavoritesFOLLOW ME:Instagram: https://www.instagram.com/integrativedrmom/Facebook:  https://www.facebook.com/integrativedrmomYouTube: https://www.youtube.com/@integrativedrmomFTC: Some links included in this description might be affiliate links. If you purchase a product through one of them, I will receive a commission (at no additional cost to you).  I truly appreciate your support of my channel. Thank you for watching! Video is not sponsored.DISCLAIMER: This podcast does not contain any medical or health related diagnosis or treatment advice. Content provided on this podcast is for informational purposes only.  For any medical or health related advice, please consult with a physician or other healthcare professionals. Further, information about specific products or treatments within this podcast are not to diagnose, treat, cure or prevent disease.

Join us in this episode as Tyler Korman, the Chief Scientific Officer and Co-Founder of eXoZymes, explains how their approach to AI-enhanced, cell-free enzyme technology is changing the way chemicals are produced… Hit play to discover: How enzymes are produced in large quantities. The ways that enzymes are used in everyday life.  The role that the microbiome plays in enzyme balance.  How sequencing data contributes to the creation of new compounds.  Tyler co-founded eXoZymes with Paul Opgenorth, building on research from the Jim Bowie Lab at UCLA. His expertise includes cell-free biomanufacturing, enzyme engineering, and AI-driven design. His work focuses on creating more efficient and sustainable methods for producing complex compounds by operating enzymes outside of living cells. To learn more about Tyler and his work, connect with him on LinkedIn!

On this episode Justin records live in Tampa FL at the Moffitt Cancer Center for this special series during CancerX 2026. His guests from the Moffitt Center are Xavier Avat, Moffitt Chief Business Officer and Dr. John Cleveland, Moffitt Center Director & Chief Scientific Officer. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

She's 70 years old, holds a PhD she earned in her late 60s, and looks like she cracked the code on aging. But Dr. Catharine Arnston isn't selling a beauty secret she's sharing 17 years of research into two of the most scientifically documented superfoods on Earth: spirulina and chlorella.In this episode of SHE MD, Mary Alice Haney and Dr. Aliabadi sit down with Dr. Catharine Arnston, Chief Scientific Officer of ENERGYbits, for one of the most eye-opening conversations we've had on this show. It started with her sister's breast cancer diagnosis and a pivot away from a 25-year corporate career. What she found in the research changed everything she thought she knew about energy, brain health, aging, and women's bodies.This isn't wellness fluff. There are over 100,000 peer-reviewed studies on these two algae. NASA has been feeding them to astronauts for 50 years. The United Nations endorsed spirulina as the answer to world hunger. And yet most women in the Western world have never heard of them.Learn More Here: https://energybits.com/discount/SHEMD?rfsn=9096638.6abd9cc1&utm_source=refersion&utm_medium=affiliate&utm_campaign=9096638.6abd9cc1What You'll LearnWhy algae was the first life on Earth and why that matters for your bodyThe difference between macroalgae (seaweed, kelp) and microalgae (spirulina, chlorella)How spirulina creates cellular energy without the crash of caffeine or sugarWhat phycocyanin is and how this blue pigment behaves differently in healthy versus unhealthy cellsWhy mitochondria decline with age and how to protect them with nutritionThe role of superoxide dismutase (SOD) and why your body stops making it after age 30Why menopause damages women's mitochondria twice as fast as men'sHow chlorella detoxes heavy metals, glyphosate, aluminum, and other environmental toxinsWhy chlorella is essential for anyone on a GLP-1 or any weight loss journeyHow chlorella naturally supports serotonin, melatonin, sleep, and bowel motilityThe right dosage of each algae by age, condition, and time of dayWhy high heat in processing kills the benefits of most algae on the marketThe truth about excess stored iron, inflammation, and "rusting from the inside" after menopauseHow ENERGYbits are sourced in Taiwan in triple-filtered mountain spring waterHow to use algae for weight loss, sleep, brain fog, skin health, and longevityKey Timestamps00:00 Welcome Dr. Catharine Arnston & Why Algae Matters00:25 Catharine's Sister, Cancer, and the Origin of ENERGYbits01:49 Plant-Based Nutrition and the Otto Warburg Discovery02:46 Why People Don't Eat Vegetables (and What to Do About It)03:28 Why No One Knows About Algae Despite 100,000 Studies04:19 Why NASA Feeds Algae to Astronauts04:43 Algae Is Food, Not a Supplement06:45 "Aging Is Natural, Declining Is Not"07:08 Macroalgae vs. Microalgae Explained08:24 Why Lake & Ocean Algae Can Be Toxic09:27 Spirulina: Energy at the Cellular Level10:22 Why Algae Protein Beats Animal Protein10:49 Dosage 101: When and How Much to Take12:13 Phycocyanin: The Blue Pigment That Targets Unhealthy Cells14:34 The Electron Transport Chain & ATP (The "Ferrari" Analogy)15:48 Aging, Mitochondria & Cellular Decline16:13 Superoxide Dismutase (SOD): The Hidden Antioxidant17:53 Why Menopause Hits Women's Mitochondria Twice as Hard19:38 Brain Fog, Depression & Damaged Mitochondria20:37 Mary Alice's Family History & The Case for Prevention22:10 How Fast You'll Feel It & Mitochondrial DNA Regeneration23:16 Anti-Angiogenesis & Stopping Tumor Blood Supply24:10 Chlorella: The Body's Tow Truck for Toxins27:45 Chlorophyll, Hemoglobin & Building Your Blood28:35 Glutathione, Liver Health & Tryptophan29:03 Chlorella, Serotonin & Mood29:34 Chlorella for Bowel Motility30:25 The Athlete Protocol (NHL & NFL Dosing)31:12 Sleep, Melatonin & Why Chlorella Works at Night32:54 Chlorella for Chemotherapy Recovery36:01 Pricing, Daily Cost & the Discount Code36:45 Important: Talk to Your Oncologist Before Combining38:17 Algae for Weight Loss & GLP-1 Support40:32 Safety, Sourcing & Why ENERGYbits Are Grown in Taiwan42:20 Catharine's Trip to Taiwan & Why It Matters43:31 Excess Iron, Menopause & "Rusting From the Inside"46:07 Final Thoughts & Why Consistency Wins47:32 Absorption, Exosomes & Why Algae Works So Fast48:39 Dosage for Kids, Husbands & Pets49:41 Beauty Bits: The Pink Spirulina for Skin & Hair51:07 Mary Alice Starts Her Algae JourneyKey TakeawaysAging is natural, declining is notAlgae is food, not a supplement, so your body recognizes and absorbs it instantlySpirulina nourishes & energizes, chlorella detoxes & repairsYou need both algaes for different reasons, especially after 40Most brain issues trace back to damaged mitochondriaWomen lose antioxidant and hormone protection twice as fast as men in menopauseThe right dosage matters more than the right ingredientConsistency beats intensity, your body is not a light switchMost supplements are artificial, your body wastes up to 90% of themToxins live in your fat, so detoxing is part of any weight loss journeyThe science exists, the connection between scientists and women is what's missingMother Nature provided answers long before pharmaceutical companies didWhat you can't see at the cellular level is often what's hurting you mostGuest BioDr. Catharine Arnston is the founder and Chief Scientific Officer of ENERGYbits, the medical-grade algae company she launched 17 years ago after pivoting from a 25-year international corporate career to research plant-based nutrition for her sister, who had been diagnosed with breast cancer. Her research led her to spirulina and chlorella, two microalgae backed by more than 100,000 scientific studies, and to a mission of bringing clean, hand-sourced algae nutrition to women, families, and elite athletes around the world. Catharine earned her health coaching certificate from the Institute for Integrative Nutrition and went on to complete her PhD in her late 60s, becoming one of the most credentialed and outspoken advocates for algae nutrition in the world. Her upcoming book, Love Your Health to Bits with Algae, set for an October release, distills 17 years of research into accessible, "science with sarcasm" guidance for the everyday reader. Catharine lives by the philosophy that "aging is natural, declining is not" and is on a mission to make algae as common in the Western world as it has been in Asia for the past 60 years.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Investigative journalist and public health expert Emily Bass returns to A Shot In The Arm with the most consequential update on the global HIV response in months. Drawing on a brand-new report from Physicians for Human Rights and South African partners — built from 40 oral histories — Emily walks Ben Plumley through the human cost of the Trump administration's foreign aid disruptions, the staggering waste of dismantled prevention infrastructure, and the bizarre data spin emerging from the State Department. The episode also covers Dr. mike Reed's headline-making resignation as PEPFAR's Chief Scientific Officer, the dangerous quiet around supply chain contracts and bed-net procurement, and what the new “America First Global Health Strategy” is choosing to celebrate — and choosing to obscure. Ben closes with a preview of two new initiatives: AIDS 2060, a long-horizon project from A Shot In The Arm Media, and the rebrand of MTV Staying Alive Foundation to Shuga Global. 00:00 Welcome and Setup 01:18 Global Health Upheaval 03:13 PEPFAR Data Spin 04:07 South Africa Report 05:51 Prevention Platform Collapse 09:27 Clinic Breakdown Story 12:52 Why 18 Percent Matters 16:33 Community Resilience 19:22 Research Partnerships Lost 22:12 Treatment Disruptions 25:26 Trauma to Transition 31:11 Data Blackout Returns 39:07 Prep Data Mirage 42:08 Kids Treatment Declines 44:55 Age Data Removed 47:02 Congress Pushback 52:02 Supply Chain Breakdown 59:38 Last Mile Disaster Story 01:02:16 Orderly Transition Demands 01:06:23 AIDS 2060 Vision 01:10:35 Sugar Global Storytelling 01:15:20 Africa Led Future 01:20:42 Closing Thanks Read Emily Bass' Substack: https://substack.com/@emilysbass Check Out Ben's Substack: https://substack.com/@benplumley1 Join the Conversation! How do you see the future of global health unfolding? Share your thoughts in the comments! Subscribe & Stay Updated: Listen on Spotify, Apple Podcasts, or your favorite podcast platform. Watch on YouTube & subscribe for more in-depth global health.

In this episode of What is a Good Life?, Mark McCartney sits down with Dave Snowden - Founder and Chief Scientific Officer of The Cynefin Co., creator of the Cynefin Framework, and one of the most original thinkers working at the intersection of complexity science, organisational design, and human decision-making.The conversation moves through substrate theory, complexity science, psychological safety, the dangers of homogenisation, coherent heterogeneity, Celtic identity, indigenous rights, conflict resolution in Northern Ireland, and what a good life really comes down to.It is a beautiful mixture of thought provoking ideas and powerful lived experiences. For more from Dave Snowden:Website: https://thecynefin.co/LinkedIn: https://www.linkedin.com/in/dave-snowden-2a93b/For more from Mark McCartney:Newsletter: https://www.whatisagood.life/Website: https://www.mmcleadership.com/LinkedIn: https://www.linkedin.com/in/mark-mccartney-14b0161b4/YouTube: https://www.youtube.com/ ⁨@whatisagoodlife3875⁩  00:00  Substrate and What Emerges02:37  Fed Up With Management Fads05:54  When Ideas Come Together07:25  Celtic Presence and Attention10:20  The Reformation's Long Shadow13:28  The Problem With Safety16:38  Phase Shifts and Flipping21:17  Changing the Granularity24:48  Witnessing Violence29:12  Identity as Flow37:43  Metaphor as Intelligence51:57  What Is a Good Life?

Send us Fan MailA child develops normally, then something changes fast and families are left asking the hardest question: what happened? I'm joined by Dr. Brian Hooker, a PhD biochemical engineer and Chief Scientific Officer at Children's Health Defense, to walk through the claims he's studied for decades about autism regression, vaccine adverse events, and why he believes the modern childhood vaccine schedule creates risks that medicine has not honestly measured.We talk about what the schedule looks like in the first year of life, why early neurodevelopment may be uniquely vulnerable, and the biological pathways he points to, including oxidative stress, immune dysregulation, neuroinflammation, aluminum adjuvants, and blood-brain barrier permeability. We also discuss why some children may be more susceptible, including the role of reduced glutathione pathways and the high rates of mitochondrial dysfunction reported in subsets of autistic children.I also share why COVID made me question “safe and effective” talking points from institutions like the CDC and FDA, and how that re-opened questions about pediatric vaccine safety studies more broadly. We get into the controversy around placebo-controlled trials, the lack of research on vaccines tested in combination as a schedule, and the real-world pressure doctors face when they speak outside the mainstream. We close with additional environmental factors raised in the conversation, including glyphosate exposure and infant acetaminophen (Tylenol), plus what twin studies may suggest about genetics versus triggers.If you want deeper, more transparent research and better questions asked on behalf of kids and parents, listen now, then subscribe, share this with a friend, and leave a review so more people can find the conversation.https://www.amazon.com/Vax-Unvax-Childrens-Health-Defense-Kennedy/dp/1510766960Support the showhttps://www.jacksonfamilyministry.comhttps://bobslone.com/home/podcast-production/

In today's episode of Health Youniversity, Dr. Susan Fox sits down with Dr. Katie Worrilow — founder and Chief Scientific Officer of Life Air Systems, postdoctoral-trained reproductive physiologist, and former scientific director of IVF programs for over 20 years — for a conversation that will change how you think about your IVF cycle.Dr. Katie spent twenty years noticing something. That when construction began outside the hospital, when the medevac pad got repaved, when the parking lot was resurfaced — clinical pregnancy rates dropped. Not because of the medicine. Not because of the protocol. Because of the air surrounding the embryo during the most critical six to seven days of its existence outside the body. That realization became Life Air Systems — a patented air purification technology now installed in 41% of US IVF programs, awarded 23 patents, over 60 registered trademarks globally, and the 2025 Edison Award for innovation in healthcare.The data from clinical studies across several thousand patients showed a nearly 20 percentage point increase in clinical outcomes with complete air quality control. Across the full installation base worldwide, the average increase in clinical pregnancy rates is 14.9 percentage points — with corresponding improvements in implantation rates and blast conversion rates.You'll learn why the air surrounding a human embryo during culture matters.  Why the environment, and chemical pathogens like toluene from warm asphalt do to embryo development — and why you won't see the damage at day 3, only at day 5.   Blastocyst conversion rates and implantation rates are the metrics that tell the real story —   air quality has to do with both. And you'll learn what questions to ask your IVF clinic before your next retrieval or transfer about air quality at the transfer stage, why the same variable that improves outcomes also reduces the likelihood of needing multiple retrieval cycles — and what that means financially and emotionally. And you'll understand why Dr. Susan is calling out fertility insurance providers and employee benefits managers in this episode directly.This episode is for you if you're preparing for an IVF cycle and want to do everything possible to optimize your outcome, you've had a beautiful day 3 embryo report followed by a devastating day 5, you've been through one or more failed cycles and are trying to figure out what to do differently before the next one, you want

In this episode, Niall speaks with Dr. Christof Koch, Chief Scientist of the MindScope Program at the Allen Institute for Brain Science, former Professor at Caltech, and author of “Then I Am Myself the World”. Dr. Koch is a leading researcher in the science of consciousness and a key proponent of Integrated Information Theory. In this conversation, they explore: — Why consciousness may be fundamental, while physical matter exists only in relation to other things — How an experience on a beach in Brazil changed his understanding of reality — The discovery of “covert consciousness” in patients thought to be in vegetative states — How the perturbational complexity index (PCI) shows a clear boundary between conscious and unconscious states, and why this matters — How Integrated Information Theory approaches the question of free will You can learn more about Dr. Koch's work at https://christofkoch.com. --- Dr. Christof Koch is a Meritorious Investigator at the Allen Institute. Christof received his baccalaureate from the Lycée Descartes in Rabat, Morocco, his B.S. and M.S. in physics from the University of Tübingen in Germany and his Ph.D. from the Max-Planck Institute for biological Cybernetics in 1982. Subsequently, he spent four years as a postdoctoral fellow in the Artificial Intelligence Laboratory and the Brain and Cognitive Sciences Department at the Massachusetts Institute of Technology. From 1987 until 2013, Koch was a professor at the California Institute of Technology (Caltech) in Pasadena, from his initial appointment as Assistant Professor, Division of Biology and Division of Engineering and Applied Sciences in 1986, to his final position as Lois and Victor Troendle Professor of Cognitive & Behavioral Biology. See here for Christof's academic pedigree and his students. Christof joined the Allen Institute for Brain Science as Chief Scientific Officer in 2011 and became President in 2015. Christof writings and interests integrate theoretical, computational and experimental neuroscience with philosophy and contemporary trends, in particular artificial intelligence. His latest book, Then I Am Myself the World: What Consciousness Is and How to Expand It, publish in May 2024. His previous book, Consciousness: Confessions of a Romantic Reductionist, blends science and memoir to explore topics in discovering the roots of consciousness. Stemming in part from a long-standing collaboration with the late Nobel Laureate Francis Crick, Christof authored the book The Quest for Consciousness: A Neurobiological Approach. Koch also authored the technical books Biophysics of Computation: Information Processing in Single Neurons and Methods in Neuronal Modeling: From Ions to Networks, and served as editor for several books on neural modeling and information processing. --- Interview Links: — Dr. Koch's website: https://christofkoch.com — Dr. Koch's book: https://amzn.to/4mIKG9W

Tara Stoinski (A Gorilla Story) is a primatologist, conservationist, and CEO and Chief Scientific Officer of the Dian Fossey Gorilla Fund. Tara returns to the Armchair Expert to discuss growing up outside Philadelphia, her academic path from Tufts to Oxford to Georgia Tech, and balancing motherhood with a career studying gorillas in Rwanda. Tara and Dax talk about documenting rare gorilla dominance battles, the challenges of filming endangered animals in the wild, and how gorilla social structures differ from chimpanzees. Tara explains the importance of long-term behavioral research, how early life trauma can impact animal behavior, and why strong social bonds are key to survival in both gorillas and humans.Take printer ink off your to-do list with HP Smart Tank | hp.com/SmartTankCheck Allstate first for a quote that could save you hundreds: https://www.allstate.com/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Day Break | From Border Battles to Cancer Controversy—And Comey Indicted Again --- 00:00 - Monologue 18:50 – Sarah Starman, Senior Food & Agriculture Campaigner at Friends of the Earth. Starman discusses the “People v. Poison” protest, where cancer survivors are speaking out against the use of RoundUp. She explains the concerns surrounding the Supreme Court case and its broader implications for public health. 27:41 – Dr. Peter A. McCullough, Chief Scientific Officer at The Wellness Company. Dr. McCullough discusses recent findings on the use of ivermectin and mebendazole in cancer treatment. He explains how these anti-parasitic drugs may work, potential next steps in research, and considerations for those interested. Visit twc.health/GRUBER and use promo code GRUBER to save 10%. 37:27 - Monologue Featuring Ivey Gruber 46:25 – Hans A. von Spakovsky, Senior Legal Fellow at the Edwin Meese III Institute for the Rule of Law. Von Spakovsky discusses ongoing controversies at the U.S. Commission on Civil Rights. He also addresses concerns about election integrity and recent legislative developments. 56:26 – Laura C. Volpe, Founder of ManeInk HairLoss Solutions. Volpe discusses solutions for preventing hair loss and thinning using targeted treatments. Visit pureance.com and use code EARLY to save 35%. 1:15:19 - Monologue 1:24:03 – Ron Rademacher, travel writer, author, and Michigan backroads expert. Rademacher shares upcoming events and seasonal activities across Michigan. He also highlights mushroom hunting and the importance of doing it safely and knowledgeably. 1:34:11 – Mike Cox, former Michigan Attorney General and candidate for governor. Cox discusses calls for transparency regarding SPLC-related documents and outlines his path to winning the governor's race. He explains the key issues shaping his campaign. 1:43:07 – Ivey Gruber, President of the Michigan Talk Network. Gruber shares a story about middle school students stepping in during a bus emergency and other notable human-interest headlines. The segment also covers unusual trends and statistics making news. --- Check out our brand new podcast, 'Forgotten America'... The twelfth episode is live NOW at Steve Gruber on YouTube! Link below: https://youtu.be/1XbEJhJ6Wrk

“Why does your body stop responding… even when you're doing everything right?” In this episode, Dr. Mariza sits down with Siobhan Mitchell to unpack the true metabolic and cellular shifts happening in perimenopause and menopause. So many women feel like their body has suddenly turned against them—weight gain, fatigue, brain fog, and rising inflammation—despite doing all the right things. But this isn't a failure of effort. It's a biological inflection point driven by declining estrogen and its impact on metabolism, mitochondria, and vascular health. Together, they break down how estrogen loss reshapes everything from blood sugar control to fat storage, mitochondrial function, and long-term cardiovascular risk—while also exploring the emerging role of gut health and phytoestrogens like S-equol as targeted support. If you've been working harder than ever with fewer results, this episode will help you understand why—and what to do instead. Be sure to tune in! SIOBHAN MITCHEL Dr. Siobhan Mitchel, PhD, is a neuroscientist and Chief Scientific Officer at MitoQ. Her work focuses on mitochondrial health, cellular energy, and the role of oxidative stress in aging—particularly in women navigating perimenopause and menopause. She is passionate about advancing research that supports women's long-term health, metabolism, and resilience at the cellular level. IN THIS EPISODE Why your body stops responding the same way in perimenopause How estrogen loss impacts metabolism, fat storage, and blood sugar The role of mitochondria in energy, brain function, and weight changes Why visceral belly fat increases—and why it's more dangerous The connection between gut health, estrogen metabolism, and inflammation How phytoestrogens (like S-equol) support metabolism and hormone signaling Why midlife is a metabolic and vascular inflection point—not just hormonal QUOTES “This isn't a failure of effort—it's a biological shift happening beneath the surface.” “When estrogen declines, you don't just lose hormones—you lose metabolic protection.” “If you support your mitochondria, you support your energy, your metabolism, and your long-term health.” RESOURCES MENTIONED Order my new book: The Perimenopause Revolution HERE! https://peri-revolution.com/ Use code ENERGIZED and get 10% off MitoQ http://www.mitoq.com/energized MitoQ Instagram MitoQ Facebook MitoQ Youtube RELATED EPISODES  693: The Cellular Shift in Perimenopause: Mitochondria, Metabolism, and Energy 728: Why Brain Fog Isn't Random: The Hormone Shift Behind It 717: “I Don't Feel Like Myself Anymore”: The Mental & Emotional Reality of Perimenopause 705: The Metabolic Shift No One Warned You About in Midlife

Join our FREE upcoming masterclass: Why Midlife Weight Gain Won't Budge A smarter way to use GLP-1s in midlife without wrecking muscle or metabolism When: April 30th 11 am PST Register here: https://coaching.karenmartel.com/glp1-masterclass   There comes a point for so many women in their late 30s and 40s when they look in the mirror, or down at their belly, and think, what is happening to my body? You're still eating well. You're still exercising. You're still trying to do all the "right" things. And yet your body suddenly feels like it is playing by a completely different set of rules. In this episode, I sit down with Dr. Siobhan Mitchell, neuroscientist, nutritional scientist, and Chief Scientific Officer at MitoQ, to unpack what is really happening beneath the surface during perimenopause and menopause. We get into the fascinating science behind estrogen loss, shifting metabolism, belly fat, blood sugar changes, mitochondrial health, and why so many women feel like their bodies stop responding the way they used to. We also talk about phytoestrogens, the gut microbiome, and a little-known molecule called S-equol that may play an important role in metabolic and hormonal health during midlife. This is a smart, eye-opening conversation for any woman who wants to better understand why midlife weight gain happens, why timing matters when it comes to intervention, and what supportive tools may actually help.   In this episode, we cover: Why midlife weight gain often shows up around the belly How estrogen affects metabolism, appetite, blood sugar, and fat storage Why women become more prone to insulin resistance in perimenopause and menopause The role of mitochondria in energy, aging, and ovarian health Why belly fat in menopause is about more than just calories How stress and cortisol can amplify fat gain during midlife The difference between estrogen alpha and beta receptors What phytoestrogens are and how they may support women in menopause What S-equol is and why it may matter for metabolic health Why early support in perimenopause may be one of the smartest moves for long-term health   Who this episode is for This episode is for women in perimenopause or menopause who feel like their metabolism has changed overnight, their belly fat is increasing for no obvious reason, or their blood sugar and weight are becoming harder to manage despite doing all the right things. It is also for women who want a deeper understanding of estrogen, midlife metabolic changes, and supportive options beyond the usual tired advice to just eat less and move more.   Key Takeaways Estrogen is not just a reproductive hormone. It plays a major role in metabolism, fat distribution, blood sugar control, and muscle maintenance. Midlife belly fat is not just about overeating or aging. Hormonal changes during perimenopause and menopause directly influence where fat is stored and how energy is used. Insulin resistance, rising cholesterol, and metabolic dysfunction can begin during perimenopause, even before obvious menopause symptoms show up. S-equol may be a promising tool for supporting estrogen-beta activity, metabolic health, and symptom relief in midlife women. The earlier women understand and support these shifts, the better their chances of protecting long-term metabolic, cardiovascular, and brain health.     http://www.mitoq.com/karenmartel Coupon code: Martel10     Sponsors Head to https://cozyearth.com and use my code HORMONESBOGO to get 2 sets of sheets for the price of one. Do not miss this sale.     Are you in perimenopause or postmenopause and struggling with symptoms—but not getting the support you deserve? At Midlife Solutions, we specialize in hormone optimization for women in midlife. Our all-female clinical team offers telehealth care across all 50 U.S. states, with the ability to prescribe bioidentical estrogen, progesterone, testosterone, and thyroid medication.   Book your FREE Hormone Discovery Call Find out what's really driving your symptoms and what your next best steps are.   Visit the website: https://karenmartel.com   Shop the Midlife Solutions Store Over-the-counter bioidentical hormone creams and oils — no prescription needed. Including: • Progesterone • Estrogen Face Cream • Vaginal Moisturizer and more!   Take the Hormone Quiz Discover hidden hormone imbalances that could be driving your symptoms. Get personalized results (and yes, they may surprise you).   Women's Peptide Weight Loss Program Clinically guided, hormone-aware weight loss for midlife women.   Midlife RESET HRT Program A complete, supportive approach to hormone replacement therapy in midlife.   Your host: Karen Martel Certified Hormone Specialist, Transformational Nutrition Coach, & Weight Loss Expert   Karen's Facebook Karen's Instagram

Why do small-scale bioprocess experiments often fail to translate in scale-up despite “perfect” results on paper?Tibor Anderlei, Chief Scientific Officer and leader of customer support at Kühner Shaker, has spent three decades solving an issue that frustrates CMC leaders and biomanufacturing teams worldwide. He pioneered online monitoring in shake flasks, co-founded AC Biotec, and now helps organizations avoid costly trial-and-error with high-throughput screening and orbital shaken bioreactors.Topics discussed:Why orbital shaken bioreactors are fundamental to successful bioprocess development (03:11)The gap between educational practices and real-world bioreactor expertise (04:00)Tibor Anderlei's journey from the Technical University of Aachen to pioneering online monitoring technology in shake flasks (04:27)Reasons why published shake flask and microtiter plate experiments often fail to be reproduced in other labs (09:47)Key parameters frequently omitted from publications—including shaking diameter—and their impact on experiment reproducibility (13:10)Practical considerations for using microtiter plates and tubes, including automation compatibility and critical shaking speeds (14:13)Common scale-up failures due to oxygen limitation and mismatched aeration rates between small-scale and bioreactor systems (22:22)The effect of bioreactor geometry, such as neck shape, on process ventilation and performance (24:49)Smart insight: If scientists want scalable, reproducible success, the path starts with getting the details right—and keeping a sharp eye on both automation trends and the fundamentals of shaken cultures.Listen to the full episode with Tibor Anderlei to unpack the real “missing links” in bioprocess reproducibility and how to bridge small-scale insight to CMC scale-up.Building a robust scale-up strategy requires looking at the process from multiple angles—regulatory, digital, and operational. Listen to those previous episodes:Episode 03 - 04: How to Master Biotech Scale-up Without Guesswork with Leonardo SibilioEpisode 25-26: 9 Critical Steps for a Seamless Transition to Large-Scale ProductionEpisode 231-232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri KornmannEpisode 233-234: Why Most Bioprocess Automation Projects Fail with Anthony CatacchioEpisode 237-238: High-Throughput Microbial Screening with Sebastian BlumConnect with Tibor Anderlei:LinkedIn: www.linkedin.com/in/tibor-anderlei-66342411/Kühner Shaker website: www.kuhner.comShaking Technology Forum: www.shakingtechnology.comSupport the show

Welcome to Episode 303 of Autism Parenting Secrets. Today we're diving into an important and timely topic… aluminum exposure. My guest is Dr. Brian Hooker, a friend of the show and Chief Scientific Officer at Children's Health Defense. He's spent decades researching environmental factors that impact neurodevelopment and helping translate complex science into practical insight for parents. Aluminum isn't something most parents think much about… and when they do, they're often told it's not a concern. But there's more to understand. Because this isn't just about where aluminum shows up… It's about how it behaves once it enters the body, particularly in relation to inflammation and the brain. Brian shares what his latest research reveals, including why aluminum adjuvants stood out, how this form of aluminum is different, and why timing during early development matters. This is about clarity… so you can make more informed decisions for your child. The secret this week is… Take Aluminum Exposure Seriously You'll Discover: Why aluminum adjuvants stood out as the most concerning exposure in recent research (3:36) How aluminum nanoparticles can travel through the body and reach the brain (5:55) The biological mechanisms linking aluminum exposure to inflammation and brain impact (11:30) Why timing of exposure during early development is critical (27:32) Practical ways parents can think about reducing exposure and making informed decisions (30:14) About Our Guest: Dr. Brian Hooker is the Chief Scientific Officer at Children's Health Defense and a leading researcher on environmental factors impacting neurodevelopment. He has authored and co-authored numerous scientific papers examining vaccine safety, toxic exposures, and autism, and is widely known for his work translating complex science into actionable insights for parents. Contact: drbrianhooker@gmail.com References In This Episode: Aluminum Adjuvants, Autoimmunity, and Autism Spectrum Disorder: A Comprehensive Mechanistic, Neuropathological, and Legal Analysis Science Unleashed 2026 - May 9, 2026 Chandler AZ Additional Resources: To learn more about personalized 1:1 support go to www.elevatehowyounavigate.com If you enjoyed this episode, share it with your friends.

Around 2018, I was living in Denver, Colorado and I was in my ongoing process of combining the fields of somatics, nutrition, nervous system, and trauma. I've wanted to learn as much as I can about all of the possible perspectives of what affects and shapes our food interactions. I was a member at the Denver Botanic Gardens and found out they were holding an all day nutrition workshop with Dr. Deanna Minich. I had been following her work for a long time and was so excited to learn from her in person. Some of the things I learned at that workshop I still cite today in sessions. I have admired the way Dr. Minich combines nutritional science and spirituality. So you can imagine how overjoyed I was when she agreed to come on the podcast and share her wisdom. In this week's episode, I chat with Dr. Deanna Minich, Nutrition Scientist and Chief Scientific Officer at Symphony Natural Health, about: Eating and circadian rhythmThe relationship between food and spiritualityFood and connection with lineage, ancestry, and generational traumaPersonal food stories and food associationsThe power of sensitivityEmbracing color, play, and creativity with food You can also read the transcript to this week's episode here: https://www.stephaniemara.com/blog/create-your-eating-timeline-to-understand-your-food-storyI hope you love this chat as much as I did and email me anytime with any insights you had from this episode! With Compassion and Empathy, Stephanie Mara FoxKeep in touch Dr. Deanna Minich: Website: https://www.deannaminich.com/ Facebook: https://www.facebook.com/deanna.minich/ Instagram: https://www.instagram.com/deannaminich/ YouTube: https://www.youtube.com/user/foodandspirit Linkedin: https://www.linkedin.com/in/deannaminich/Support the showKeep in touch with Stephanie Mara:Instagram: https://www.instagram.com/_stephaniemara/Facebook: https://www.facebook.com/stephaniemarafoxWebsite: https://www.stephaniemara.com/https://www.somaticeating.com/Linkedin: https://www.linkedin.com/in/stephmara/TikTok: https://www.tiktok.com/@stephaniemarafoxContact: support@stephaniemara.comSupport the show:Become a supporter: https://www.buzzsprout.com/809987/supportAll affiliate links: https://www.stephaniemara.com/resourcesReceive 15% off my fave protein powder with code STEPHANIEMARA at checkout here: https://www.equipfoods.com/STEPHANIEMARAUse my Amazon Affiliate link when shopping on Amazon: https://amzn.to/448IyPlSpecial thanks to Bendsound for the music in this episode. www.bensou...

In this episode of Resiliency Radio with Dr. Jill, Dr. Jill Carnahan explores the complex and rapidly evolving science behind Long COVID and autoimmune disease with Dr. Aristo Vojdani, a leading expert in immunology and functional medicine. Dr. Vojdani shares decades of groundbreaking research into how the immune system becomes dysregulated, revealing how infections, environmental toxins, and food antigens can trigger autoimmune reactions through mechanisms like molecular mimicry and gut permeability. The conversation dives deep into how SARS-CoV-2, Epstein-Barr Virus (EBV), and HHV6 contribute to Long COVID and neuroautoimmune conditions, as well as how early detection through advanced laboratory testing may help prevent disease progression. This episode offers powerful insights for both clinicians and patients seeking to understand the root causes of autoimmunity and chronic illness in the post-COVID era.

Your standard labs came back normal, but your cells might still be starving for energy. If you're doing everything right (the supplements, the diet, the sleep) but still can't shake the exhaustion, the problem might not show up on any bloodwork. What most providers never check is what's happening inside your cells: specifically how well your mitochondria are producing energy, and whether your circulation is quietly declining over time. In this episode, you'll learn: Why standard lab panels miss what's actually driving fatigue at the cellular level What mitochondria really do and how their decline leads to brain fog, weakness, and exhaustion The key supplements with real science behind them: CoQ10, L-carnitine, creatine, lipoic acid, and NAD The truth about nitric oxide: when it supports circulation and when it becomes a problem Why blood flow may be one of the most overlooked factors in chronic fatigue and long COVID recovery Guest: Dr. Luke Bucci is the Chief Scientific Officer of Juvenon, a clinical nutritionist, and a recognized leader in nutritional science with 37+ years in the dietary supplement industry working with Nobel Prize-winning scientists. He's also the recipient of the Science and Innovation Icon Award for his decades-long leadership and innovation in nutritional science and the dietary supplement industry. Discover your fatigue score and the root causes keeping you stuck: https://myfatiguescore.com Free Fatigue Masterclass: https://www.energymdmethod.com/masterclass See real client results: https://energymdmethod.com/results Chapters: 00:00 - Introduction 00:28 - Meet Luke Bucci, PhD 01:00 - Why Standard Labs Miss What's Happening Inside Your Cells 02:30 - What Mitochondria Actually Are 04:25 - What Happens When Mitochondria Don't Work Well 08:10 - Autophagy: How Your Body Takes Out the Trash 10:01 - Exercise, Isometrics and Mitochondrial Health 14:45 - Creatine: Not Just for Bodybuilders 17:10 - How Creatine Works in the Brain and Muscles 20:30 - CoQ10, L-Carnitine and Lipoic Acid for Energy 26:15 - Why Supplements Aren't Enough on Their Own 30:00 - Nitric Oxide, Blood Flow and Fatigue 34:10 - The Risks of Too Much Nitric Oxide 37:30 - Arginine Silicate and Polyphenols Explained 40:45 - Juvenon Products and Final Thoughts Connect with Dr. Luke Bucci: Juvenon Website: https://juvenon.com/ Subscribe to the EnergyMD Podcast for weekly conversations with leading experts on resolving ME/CFS and Long COVID by addressing the real root causes. . For more information about Evan and his program, Click Here.   Prefer to watch on Youtube? Click Here.   Please note that any information in this episode is for educational purposes only and does not constitute medical advice.

Vaccine policy, public health messaging, and medical freedom are rapidly shifting, leaving many parents and practitioners feeling uncertain about what to trust. In this episode, Dr. Jen sits down with Dr. Peter McCullough to unpack recent changes in vaccine policy, the role of federal and state-level decisions, and the growing conversation around informed consent and risk stratification. They discuss measles outbreaks, treatment approaches, and the importance of individualized care, while also exploring concerns around vaccine safety, scheduling, and long-term outcomes. This conversation offers a broader perspective on navigating health decisions in a complex and evolving medical landscape.Dr. Peter McCullough, MD, MPH, is an internist, cardiologist, and epidemiologist with over 1,000 scientific publications. He currently serves as Chief Scientific Officer for The Wellness Company and President of the McCullough Foundation. His work focuses on public health policy, informed consent, and advancing approaches to early treatment and patient-centered care. Dr. McCullough is a frequent speaker and advocate for medical freedom and individualized healthcare decisions.Website: https://petermcculloughmd.com Instagram: https://www.instagram.com/petermcculloughmd Facebook: https://www.facebook.com/Dr.Peter.McCulloughMD X: https://x.com/P_McCulloughMDYouTube: https://www.youtube.com/@petermcculloughmdLinkedIn: https://www.linkedin.com/in/petermcculloughmd PODCAST: Thank you for listening please subscribe and share! Shop supplements: https://healthybydrjen.shop/CHECK OUT a list of my Favorite products here: https://www.healthybydrjen.com/drjenfavoritesFOLLOW ME:Instagram: https://www.instagram.com/integrativedrmom/Facebook:  https://www.facebook.com/integrativedrmomYouTube: https://www.youtube.com/@integrativedrmomFTC: Some links included in this description might be affiliate links. If you purchase a product through one of them, I will receive a commission (at no additional cost to you).  I truly appreciate your support of my channel. Thank you for watching! Video is not sponsored.DISCLAIMER: This podcast does not contain any medical or health related diagnosis or treatment advice. Content provided on this podcast is for informational purposes only.  For any medical or health related advice, please consult with a physician or other healthcare professionals. Further, information about specific products or treatments within this podcast are not to diagnose, treat, cure or prevent disease.

DR1In our 'Asshole is selfish' headline of the week. Billionaire Uber co-founder Travis Kalanick admits strategically moving to Texas before California wealth tax***************Kalanick was caught on camera in a heated argument with an Uber driver, who complained about falling fares and the company's treatment of drivers: "Some people don't like to take responsibility for their own sh*t"In our 'Top snarky podcast hosts plead with airline companies to stop the share buyback bullshit and pay airport workers. ‘Once again, air travel CEOs are bullshit artists'' headline of the week. Top airline CEOs plead with Congress to restore DHS funding and pay airport workers. ‘Once again, air travel is the political football'***************Between June 1, 2025, and March 16, 2026:Southwest repurchased $2.6B in 2005; $400M in 2026United $1.5B5 NEOs: $91 million in 2025Scott Kirby $34M; $97M in shares Delta focused on $4.8B debt reductionFrontline Transportation Security Officers (TSOs, Airport Screeners): 50,000$328M per monthIn our 'Pervy owner does pervy stuff and everybody is fake shocked.' headline of the week. It Was Going to Be Magic City Night at the Atlanta Hawks. Then the Outrage Poured In.***************Tony Ressler founded the private equity firm Apollo Global Management with Leon Black.An independent review revealed that Leon Black paid Jeffrey Epstein $158M for financial and tax-planning services between 2012 and 2017. These payments occurred after Epstein's 2008 conviction for soliciting an underage girl.Ressler is the brother-in-law of Leon Black (Black is married to Ressler's sister, Debra) In our 'College dropout techbro ignores actual experts, part 17 million ' headline of the week. OpenAI's own mental health experts unanimously opposed “naughty” ChatGPT launch*************** The probably might be too many women and not enough Stanford? The council consists of the following eight independent experts:David Bickham, Ph.D. – Research Director at the Digital Wellness Lab at Boston Children's Hospital and Assistant Professor at Harvard Medical SchoolMathilde Cerioli, Ph.D. – Chief Scientific Officer at everyone.AI and researcher in cognitive neuroscience and psychologyMunmun De Choudhury, Ph.D. – Professor of Interactive Computing at Georgia Tech, specializing in how technology shapes mental healthTracy Dennis-Tiwary, Ph.D. – Professor of Psychology at Hunter College and co-founder/CSO of Arcade TherapeuticsSara Johansen, M.D. – Clinical Assistant Professor at Stanford University and founder of Stanford's Digital Mental Health ClinicDavid Mohr, Ph.D. – Professor at Northwestern University and Director of the Center for Behavioral Intervention TechnologiesAndrew K. Przybylski, Ph.D. – Professor of Human Behavior and Technology at the University of OxfordRobert K. Ross, M.D. – Former President and CEO of The California Endowment and a national leader in public health.In addition to the council's pushback, Ryan Beiermeister, OpenAI's head of product policy, was reportedly fired in January 2026 after being an outspoken internal critic of the erotica rollout. OpenAI has denied her dismissal was related to her opposition, citing separate workplace allegations that Beiermeister has called "absolutely false."In our 'Petulant manchild with no regulatory or societal guardrails screws up again and bails himself out with shareholder money from a different company' headline of the week. Elon Musk admits xAI ‘wasn't built right' as only 2 co-founders remain and its biggest AI bet stalls out***************The people leaving xAI right now aren't "legacy" employees—they are the hand-picked superstars Musk himself recruited in 2023 to build his AI dream.Out of the 12 original co-founders, 10 are gone. This isn't just "trimming the fat"; it's the original architects of the company walking out the door.In early 2026, Tesla (a public company) invested $2B into xAI.Tesla shareholders are furious, arguing that Musk used their money to fund a "broken" startup, then tucked it away inside his private SpaceX empire where there is less public oversight.Total Headcount Before Buyout: Approximately 7,500 to 8,000 employees.In his first week, Musk fired roughly 50% of the staff (about 3,700 people) overnight.Shortly after, he issued his famous "extremely hardcore" memo. When hundreds of employees refused to sign it and resigned instead, the headcount plummeted further.By April 2023, Musk confirmed in a BBC interview that the workforce had been slashed by 80%, leaving only about 1,500 employees. MM1In our 'The world's most stable billionaire announces a billionaire to all other billionaires ratio of 693:1' headline of the week. Elon Musk Is Now Worth More Than Bottom 693 Billionaires CombinedIn our 'In news celebrated worldwide, older women announce a "please save us from tech bros" to asshole ratio of 64:1 Elon Musk' headline of the week. Older women set to inherit most of $54 trillion in ‘great wealth transfer' to widowed spousesIn our 'Asshole wants you to know he is still here' headline of the week. ‘I never left': Travis Kalanick launches new robotics company Atoms with manifesto"At Atoms we make gainfully employed robots — specialized robots with productive jobs that bring abundance to their owners and society at large,"In our 'Company founder announces major "stealth mode" company perk is stealthy sexual harassment' headline of the week. Travis Kalanick sees benefits of being in stealth mode for 8 years. ‘You build a culture of people that want to build and do not need to be famous'In our 'Christmas, St. Patrick, Mel Gibson, and Casper the Friendly Ghost have reportedly filed complaints with the EEOC' headline of the week. Nike and Coca-Cola cases point to the next DEI fight: who gets to claim discriminationDR2In our 'Sheryl Sandberg says "If I could have worked at Facebook things would have turned out differently."' headline of the week. Sheryl Sandberg says Silicon Valley's hypermasculine rhetoric is ‘terrible'—contributing to ‘one of the worst' corporate climates she's ever seen*************** In our 'Explosive Messages Show Live Nation Thinks Customers Are ‘Stupid'; board member Richard Grenell Demands Credit for Same Observation' headline of the week. Live Nation Directors Mocked Customers in Explosive Just-Released Messages, Saying They're “Stupid” for Allowing Themselves to Be Gouged***************"Yes, I cut the DEI bullshit." — In a leaked 2025 email Grenell justified dismantling diversity programs by labeling them "woke" initiatives that "haven't made money."appointed to the Live Nation board on May 19, 2025, but was not up for the vote at the AGM on June 12, 2025In our 'Gun manufacturers say, "Oh no, it's not the gun that kills people, it's the pesky bullets."' headline of the week. She spent 16 hours on Instagram in a day. It's up to a jury to decide if Meta is to blame*************** In our 'She responded to "O" with "K," she said "J' to "D," and she responded to "F" with a simple "U"' headline of the week. Mary Barra still responds to ‘every single letter' she gets by hand despite running $65 billion automaker General Motors***************She did not say "V" to "E"In our 'OpenAI Chairman Admits It's Painful Watching AI Replace His Coding, Less So Watching It Accelerate the Collapse of Global Democracy' headline of the week. OpenAI Chairman says it's 'hard, emotionally' to let AI write his code: 'I have a hard time not caring'*************** MM2In our 'Proposals include a reduction in the CEO pay ratio from 1800:1 to 1799:1, for my boss to stop calling me Carl when my name is Todd, having a job, and not to have to take out my nose ring I got in 1998' headline of the week. Starbucks union sent the company a proposed contract. Here's what baristas wantProtections for union baristas against discrimination, unjust firings and temporary or permanent store closures.Starting wage floor of $17 per hour, down from its prior proposal of $20 an hour but still above the company's current starting wage of $15.25 to $16 an hour in 43 states.Annual raises of 4%.A process for baristas, management and union representatives to resolve workforce grievances.A dress code endorsed by the union.Requirement for at least three workers on the floor at all times and enforceable staffing and safety protections.A mandate to offer open hours to existing employees before hiring new baristas.Resolution of hundreds of outstanding unfair labor practice charges.In our 'But Sam Altman is SORRY' headline of the week. Professors Say AI Is Destroying Their Students' Ability to ThinkIn our 'Don't be fooled, I'm actually a MAN' headline of the week. CoStar Group Appoints Nana Banerjee to Its Board of DirectorsI pulled every Trade Wire story with a director appointment - 69 in the last week, all press released, some private some public - and here's the count: 60 men added to boards, 9 women added, 1 woman leftIn our 'Building on Warren Buffet's innovative "Giving Pledge", billionaire creates the rival "Taking Pledge"' headline of the week. Peter Thiel is actively convincing billionaires to abandon The Giving Pledge — and it's workingIn our 'When asked for comment, ISS asked if Nelson Peltz was involved.' headline of the week. The Coca-Cola Company Announces Maria Elena Lagomasino Will Conclude Her Service on the Board of Directors